<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metronidazole (systemic): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metronidazole (systemic): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Metronidazole (systemic): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9589" href="/d/html/9589.html" rel="external">see "Metronidazole (systemic): Drug information"</a> and <a class="drug drug_patient" data-topicid="12250" href="/d/html/12250.html" rel="external">see "Metronidazole (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F8770965"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Carcinogenic:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Metronidazole has been shown to be carcinogenic in mice and rats. Avoid unnecessary use of metronidazole. Reserve metronidazole for use in the following indications: trichomoniasis, amebiasis, and anaerobic bacterial infections.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8770969"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Flagyl;</li>
<li>Likmez</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869241"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-MetroNIDAZOLE;</li>
<li>Auro-MetroNIDAZOLE;</li>
<li>Flagyl;</li>
<li>MINT-Metronidazole;</li>
<li>PMS-MetroNIDAZOLE</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10529895"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Amebicide</span>;</li>
<li>
<span class="list-set-name">Antibiotic, Anaerobic</span>;</li>
<li>
<span class="list-set-name">Antiprotozoal</span></li></ul></div>
<div class="block don drugH1Div" id="F53462663"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b>Limited data available; dosing regimens variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2','lexi-content-ref-22252819','lexi-content-ref-23587979','lexi-content-ref-32453198','lexi-content-ref-33902072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2','lexi-content-ref-22252819','lexi-content-ref-23587979','lexi-content-ref-32453198','lexi-content-ref-33902072'])">Ref</a></span>): IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Postmenstrual Age (PMA)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Loading Dose<sup>a</sup></b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Maintenance Dose</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> Initiate maintenance dosing following the loading dose at the interval that will be used for maintenance dosing.</p></td></tr></tfoot>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">24 to &lt;34 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg/kg/dose every 12 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">34 to 40 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg/kg/dose every 8 hours</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">&gt;40 weeks</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg/kg</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg/kg/dose every 6 hours <b>or</b> 10 mg/kg/dose every 8 hours</p></td></tr></tbody></table>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Limited data available: <b>Note:</b> Use in combination with other antibiotics as appropriate for surgical procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35203881','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35203881','lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35203881','lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35203881','lexi-content-ref-23327981'])">Ref</a></span>): IV:</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">
<b>Body Weight</b></p></td>
<td align="center">
<p style="text-indent:0em;">
<b>Dose</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;1.2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">7.5 mg/kg as a single dose 30 to 60 minutes prior to surgical incision</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥1.2 kg</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg/kg as a single dose 30 to 60 minutes prior to surgical incision</p></td></tr></tbody></table></div>
</div>
</div>
<div class="block dop drugH1Div" id="F8771168"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 15 to 50 mg/kg/<b>day</b> in divided doses every 8 hours; maximum daily dose: 2,250 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 22.5 to 40 mg/kg/<b>day</b> in divided doses every 6 or 8 hours; maximum daily dose: 4,000 mg/<b>day</b>.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24f8b94b-8175-4acf-84b6-365a2ea892f9">Amebiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amebiasis:</b> Infants, Children, and Adolescents: Oral, IV: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 7 to 10 days; maximum dose: 750 mg/dose; followed by an intraluminal agent (eg, paromomycin). Reserve IV therapy for severe infection or extraintestinal disease and switch to oral therapy when tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f74ecf56-4df6-48d7-b60e-9165458d8fec">Bacterial vaginosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial vaginosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;45 kg: Oral: 15 to 25 mg/kg/<b>day</b> in divided doses every 8 hours for 7 days; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥45 kg and Adolescents: Oral: 500 mg every 12 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd1ac525-b3cd-4a2a-a2c6-508340b51bda">Balantidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Balantidiasis:</b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 5 days; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bda31d3-8c70-4c8c-9bda-588b02753ab9">
<i>Clostridioides difficile</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants: <i>Mild to moderate infection</i>: Oral, IV: 7.5 mg/kg/dose every 6 hours for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nonsevere infection, initial or first recurrence: </i>Oral: 7.5 mg/kg/dose every 6 to 8 hours for 10 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe/fulminant infection, initial: </i>IV: 10 mg/kg/dose every 8 hours for 10 days; maximum dose: 500 mg/dose; use concomitantly with oral or rectal vancomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29462280'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b09fb557-34eb-4113-9f49-d92c9cddc84a">Crohn disease, perianal disease; induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease, perianal disease; induction (adjunctive agent):</b> Children and Adolescents: Oral: 20 to 30 mg/kg/<b>day </b>in divided doses every 8 to 12 hours as part of an appropriate combination regimen; maximum dose: 500 mg/dose. Reported duration variable; may be continued for ~4 to 12 weeks; overall duration of induction therapy dependent on clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20081543','lexi-content-ref-31799497','lexi-content-ref-33026087','lexi-content-ref-29420227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20081543','lexi-content-ref-31799497','lexi-content-ref-33026087','lexi-content-ref-29420227'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc754735-9453-40c0-8f70-91821b2d963a">Dientamoeba fragilis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dientamoeba fragilis:</i></b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 10 days; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9938d465-584f-48f7-8083-e90bc984c47e">Exit-site or tunnel infection, peritoneal dialysis catheter</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Exit-site or tunnel infection, peritoneal dialysis catheter:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg/dose every 8 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a7088e0-7d0f-47f9-85ee-4c73938d530d">Giardiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giardiasis:</b> Infants, Children, and Adolescents: Oral: 5 mg/kg/dose every 8 hours for 5 to 7 days; maximum dose: 250 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.3','lexi-content-ref-11148005','lexi-content-ref-23235648','lexi-content-ref-AAP.2','lexi-content-ref-23656647']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.3','lexi-content-ref-11148005','lexi-content-ref-23235648','lexi-content-ref-AAP.2','lexi-content-ref-23656647'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Helicobacter pylori</b></i>
<b>eradication:</b> Limited data available: <b>Note:</b> Use as part of an appropriate combination regimen; usual duration of therapy is 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28541262'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing:</i> Children and Adolescents: Oral: 10 to 15 mg/kg/dose twice daily; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21701406','lexi-content-ref-28653787','lexi-content-ref-24117692','lexi-content-ref-27629844','lexi-content-ref-21558964','lexi-content-ref-25171023','lexi-content-ref-21407111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21701406','lexi-content-ref-28653787','lexi-content-ref-24117692','lexi-content-ref-27629844','lexi-content-ref-21558964','lexi-content-ref-25171023','lexi-content-ref-21407111'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28541262'])">Ref</a></span>): Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">15 to &lt;25 kg: Oral: 250 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:6em;">25 to &lt;35 kg: Oral: 500 mg in the morning and 250 mg in the evening <b>or</b> 375 mg twice daily (if using liquid preparation).</p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg: Oral: 500 mg twice daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection: Note:</b> Use as part of an appropriate combination regimen. Treatment duration should be limited to 4 to 7 days after source control; longer durations are required when source control inadequate; in some circumstances (eg, acute appendicitis without perforation) therapy should be limited to ≤24 hours (Hurst 2017, IDSA [Solomkin 2010], SIS [Mazuski 2017]). (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26703242','lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26703242','lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Divided dosing: </i>Infants, Children, and Adolescents: IV: 30 to 40 mg/kg/<b>day</b> in divided doses every 8 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12596112','lexi-content-ref-20034345','lexi-content-ref-Yardeni.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12596112','lexi-content-ref-20034345','lexi-content-ref-Yardeni.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Once-daily dosing:</i> Appendicitis: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;80 kg: IV: 30 mg/kg/dose every 24 hours; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29788329','lexi-content-ref-20620320','lexi-content-ref-26703242','lexi-content-ref-16677904','lexi-content-ref-18558169','lexi-content-ref-Yardeni.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29788329','lexi-content-ref-20620320','lexi-content-ref-26703242','lexi-content-ref-16677904','lexi-content-ref-18558169','lexi-content-ref-Yardeni.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥80 kg: IV: 1,500 mg every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29788329','lexi-content-ref-26703242']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29788329','lexi-content-ref-26703242'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease:</b> Adolescents: Oral, IV: 500 mg every 12 hours for 14 days as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0f834ed6-d309-4877-a1b1-30a17a66edc2">Peritonitis in patients receiving peritoneal dialysis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis in patients receiving peritoneal dialysis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i> Gastrointestinal or genitourinary procedures: Infants, Children, and Adolescents: IV: 10 mg/kg once prior to procedure in combination with cefazolin; maximum dose: 1,000 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> Infants, Children, and Adolescents: Oral: 10 mg/kg/dose every 8 hours; maximum dose: 400 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6656758-3f76-4617-9e5b-e7d8d68c83a8">Sexually transmitted infections, empiric treatment following sexual assault in females</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections, empiric treatment following sexual assault in females</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescent females: Oral: 500 mg every 12 hours for 7 days as part of an appropriate combination regimen.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b976b88-c8e8-47cc-a9b2-253040d56ea0">Small intestinal bacterial overgrowth</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small intestinal bacterial overgrowth: </b>Very limited data available: <b>Note: </b>Optimal dosing regimen and duration of therapy are unknown; some prescribers report alternating courses of different antibiotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35274342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35274342'])">Ref</a></span>). Dosing based on small descriptive studies and published recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Usual dose: 10 mg/kg/dose every 12 hours for 7 to 14 days. Maximum dose has not been established for this indication; however, a maximum of 500 mg/dose has been used for other indications. Reported range: 5 to 10 mg/kg/dose every 8 to 12 hours; may also consider guideline-recommended adult dose of 250 mg every 8 hours in appropriately sized patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18042954','lexi-content-ref-21258668','lexi-content-ref-37168915','lexi-content-ref-34156541','lexi-content-ref-32023228','lexi-content-ref-23974062']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18042954','lexi-content-ref-21258668','lexi-content-ref-37168915','lexi-content-ref-34156541','lexi-content-ref-32023228','lexi-content-ref-23974062'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b> Children and Adolescents: IV: 15 mg/kg as a single dose 30 to 60 minutes prior to procedure; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Surgical prophylaxis, colorectal:</i> Children and Adolescents: Oral: 15 mg/kg/dose every 3 to 4 hours for 3 doses, starting after mechanical bowel preparation the afternoon and evening before the procedure, with or without additional oral antibiotics and with an appropriate IV antibiotic prophylaxis regimen; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52f26aeb-8096-4aee-987a-92382ab5d9d0">Tetanus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tetanus (<i>Clostridium tetani</i> infection):</b> Infants, Children, and Adolescents: IV, Oral: 30 mg/kg/<b>day</b> in divided doses every 8 hours for 7 to 10 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.3','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.3','lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="607d0c6b-b0b3-417f-8e04-0e74854962f4">Trichomoniasis; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trichomoniasis; treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;45 kg: Oral: 45 mg/kg/<b>day</b> in divided doses every 8 hours for 7 days; maximum daily dose: 2,000 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥45 kg and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: Oral: 500 mg every 12 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Males: Oral: 2,000 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b08c896-ff74-49e1-931a-68ccf013b13f">Ulcerative colitis, pouchitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ulcerative colitis, pouchitis:</b> Children and Adolescents: Oral: 20 to 30 mg/kg/<b>day</b> in divided doses every 8 hours for 14 days; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30044357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30044357'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130088"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild, moderate, or severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; however, decreased renal function does not alter the single-dose pharmacokinetics.</p>
<p style="text-indent:-2em;margin-left:6em;">ESRD requiring dialysis: Metronidazole metabolites may accumulate; monitor for adverse events; accumulated metabolites may be rapidly removed by dialysis.</p>
<p style="text-indent:-2em;margin-left:8em;">Intermittent hemodialysis (IHD): If administration cannot be separated from hemodialysis, consider supplemental dose following hemodialysis.</p>
<p style="text-indent:-2em;margin-left:8em;">Peritoneal dialysis (PD): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate dosing: Others have used the following adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Arnoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Arnoff.1'])">Ref</a></span>). <b>Note:</b> Renally adjusted dose recommendations are based on doses of 15 to 30 mg/kg/<b>day</b> divided every 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥10 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 4 mg/kg/dose every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent hemodialysis (IHD): Extensively removed by hemodialysis: 4 mg/kg/dose every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis (PD): Extensively removed by peritoneal dialysis: 4 mg/kg/dose every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): No adjustment required.</p></div>
<div class="block dohp drugH1Div" id="F51130089"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No dosage adjustment necessary; use with caution and monitor for adverse events.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Reduce dose by 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). Based on experience in adult patients, the dosing interval may be prolonged while maintaining the usual individual dose (eg, administration of the usual dose but scheduling it every 12 hours instead of every 6) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3435113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3435113'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F8771169"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9589" href="/d/html/9589.html" rel="external">see "Metronidazole (systemic): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d920f8e-db27-4efd-b015-d6656cfc2c64">Amebiasis, intestinal or extraintestinal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amebiasis, intestinal (acute dysentery) or extraintestinal (liver abscess):</b>
<b>Oral:</b> 500 to 750 mg every 8 hours for 7 to 10 days followed by an intraluminal agent (eg, paromomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DPI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DPI.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f74ecf56-4df6-48d7-b60e-9165458d8fec">Bacterial vaginosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bacterial vaginosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment is generally not warranted for patients who are asymptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-28729110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-28729110'])">Ref</a></span>). For multiple disease recurrences, 500 mg twice daily for 7 days in combination with or prior to a multiweek course of boric acid, followed by suppressive topical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-19704395','lexi-content-ref-Sobel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-19704395','lexi-content-ref-Sobel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd1ac525-b3cd-4a2a-a2c6-508340b51bda">Balantidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Balantidiasis (alternative agent) (off-label use):</b>
<b>Oral:</b> 500 to 750 mg 3 times daily for 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2013','lexi-content-ref-DPI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2013','lexi-content-ref-DPI.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb1f0aaf-41ff-4651-ad53-d81e2f072c7d">Bite wound infection, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis or treatment (animal or human bite) (alternative agent) (off-label use):</b>
<b>Oral, IV:</b> 500 mg every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2019b','lexi-content-ref-Baddour.2019a','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2019b','lexi-content-ref-Baddour.2019a','lexi-content-ref-24947530'])">Ref</a></span>). Duration is 3 to 5 days for prophylaxis; duration of treatment for established infection is typically 5 to 14 days and varies based on clinical response and patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2019b','lexi-content-ref-Baddour.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2019b','lexi-content-ref-Baddour.2019a'])">Ref</a></span>). <b>Note: </b>For animal bites, use in combination with an appropriate agent for <i>Pasteurella multocida</i>. For human bites, use in combination with an appropriate agent for <i>Eikenella corrodens</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c05ef37d-c875-44c5-bf42-41a4ee5c44d5">
<i>Clostridioides difficile</i> infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Clostridioides difficile</i> infection, treatment (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Criteria for disease severity is based on expert opinion and should not replace clinical judgment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonsevere (ie, WBC ≤15,000 cells/mm<sup>3</sup> and serum creatinine &lt;1.5 mg/dL), initial episode (alternative agent if oral vancomycin or fidaxomicin unavailable or contraindicated):</i>
<b>Oral:</b> 500 mg 3 times daily for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34164674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34164674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fulminant infection (ie, ileus, megacolon, and/or hypotension/shock):</i>
<b>IV:</b> 500 mg every 8 hours in combination with oral and/or rectal vancomycin for 10 days; may be extended up to 14 days if patient has improved but has not had symptom resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34003176','lexi-content-ref-34164674','lexi-content-ref-Kelly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34003176','lexi-content-ref-34164674','lexi-content-ref-Kelly.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="698502f2-8371-4f7b-b52e-f26b1c2278b7">Crohn disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Crohn disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Management after surgical resection: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Monotherapy</i>: <b>Oral:</b> 20 mg/kg/day (in 3 divided doses) <b>or</b> 1 to 2 g/day in divided doses for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508','lexi-content-ref-7768364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508','lexi-content-ref-7768364'])">Ref</a></span>); begin as soon as oral intake is resumed after surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7768364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7768364'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Combination therapy</i>: <b>Oral:</b> 250 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18727929','lexi-content-ref-28402454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18727929','lexi-content-ref-28402454'])">Ref</a></span>) <b>or</b> 1 to 2 g/day in divided doses for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>); begin as soon as oral intake is resumed after surgery and administer in combination with a thiopurine (azathioprine or mercaptopurine) or a TNF-alpha inhibitor (eg, adalimumab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18727929','lexi-content-ref-25542620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18727929','lexi-content-ref-25542620'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Treatment of simple perianal fistulas (adjunctive agent):</b>
<b>Oral:</b> 500 mg twice daily for 4 weeks initially; if clinical response (ie, cessation of drainage and closure of fistula), continue at 250 mg 3 times daily for an additional 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bitton.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bitton.2019'])">Ref</a></span>) <b>or</b> 10 to 20 mg/kg/day in divided doses for 4 to 8 weeks with or without ciprofloxacin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29610508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29610508'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c1de4625-95d4-4250-b714-a36f60a5769a">
<i>Dientamoeba fragilis</i> infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dientamoeba fragilis </b></i>
<b>infection (off-label use): Oral:</b> 500 to 750 mg 3 times daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-24533282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-24533282'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a7088e0-7d0f-47f9-85ee-4c73938d530d">Giardiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Giardiasis (alternative agent) (off-label use):</b>
<b>Oral:</b> 250 mg 3 times daily <b>or</b> 500 mg 2 times daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bartelt.2018','lexi-content-ref-DPI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bartelt.2018','lexi-content-ref-DPI.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Helicobacter pylori </b></i>
<b>eradication (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Clarithromycin triple regimen</i>: <b>Oral:</b> Metronidazole 500 mg 3 times daily in combination with clarithromycin 500 mg twice daily and a standard-dose or double-dose proton pump inhibitor (PPI) twice daily; continue regimen for 14 days. <b>Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates ≥15%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-27102658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-27102658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bismuth quadruple regimen</i>: <b>Oral:</b> Metronidazole 250 mg 4 times daily <b>or</b> 500 mg 3 or 4 times daily in combination with either bismuth subsalicylate 300 to 524 mg or bismuth subcitrate 120 to 300 mg 4 times daily, tetracycline 500 mg 4 times daily, and a standard-dose PPI twice daily; continue regimen for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-27102658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-27102658'])">Ref</a></span>). <b>Note:</b> When used for salvage therapy, high-dose metronidazole (500 mg 3 or 4 times daily) is recommended with a total regimen duration of 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33524402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33524402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Concomitant regimen</i>: <b>Oral:</b> Metronidazole 500 mg twice daily in combination with clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, and a standard-dose PPI twice daily; continue regimen for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-27102658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-27102658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sequential regimen (alternative regimen)</i>: <b>Oral:</b> Amoxicillin 1 g twice daily plus a standard-dose PPI twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard-dose PPI twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659'])">Ref</a></span>); some experts prefer the 10-day sequential regimen (amoxicillin for 5 days, followed by metronidazole and clarithromycin for 5 days) over the 14-day sequential regimen (amoxicillin for 7 days, followed by metronidazole and clarithromycin for 7 days) due to the lack of data showing superiority of the 14-day regimen over the 10-day regimen in North America (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-Lamont.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-Lamont.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hybrid regimen (alternative regimen)</i>: <b>Oral:</b> Amoxicillin 1 g twice daily plus a standard-dose PPI twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard-dose PPI twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-25381839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-25381839'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Empiric oral regimens may be appropriate for patients with mild to moderate infection. Other patients may be switched from IV to oral therapy at the same dose when clinically improved and able to tolerate an oral diet (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573','lexi-content-ref-20034345']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573','lexi-content-ref-20034345'])">Ref</a></span>). The addition of metronidazole may not be necessary for uncomplicated biliary infection of mild to moderate severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-Vollmer.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-Vollmer.2019'])">Ref</a></span>). For acute diverticulitis, some experts suggest deferring antibiotics in otherwise healthy patients who are immunocompetent with mild disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-34183510','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26453777','lexi-content-ref-30664553','lexi-content-ref-34183510','lexi-content-ref-28719679','lexi-content-ref-28085573','lexi-content-ref-32073652'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IV:</b> 500 mg every 8 hours as part of an appropriate combination regimen. Duration of therapy is 4 to 5 days following adequate source control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25992746','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25992746','lexi-content-ref-28085573'])">Ref</a></span>). For diverticulitis or uncomplicated appendicitis managed without intervention, duration is 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barshak.2018','lexi-content-ref-Pemberton.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barshak.2018','lexi-content-ref-Pemberton.2018'])">Ref</a></span>); for perforated appendicitis managed with laparoscopic appendectomy, 2 to 4 days may be sufficient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36669519','lexi-content-ref-25992746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36669519','lexi-content-ref-25992746'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5330bca6-503f-4514-a8e2-2b7e43dcf6da">Intracranial abscess</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracranial abscess (brain abscess, intracranial epidural abscess)</b>
<b>:</b>
<b>IV:</b> 7.5 mg/kg (usually 500 mg) every 6 to 8 hours (maximum dose: 4 g/day) for 6 to 8 weeks in combination with other appropriate antimicrobial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29909695','lexi-content-ref-Sexton.2018b','lexi-content-ref-Southwick.2018','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29909695','lexi-content-ref-Sexton.2018b','lexi-content-ref-Southwick.2018','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> May switch IV metronidazole to oral metronidazole at the same dose to complete treatment course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Southwick.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Southwick.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e93e521b-dcf8-4c9e-a517-ce735b97e18a">Odontogenic infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Odontogenic infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute simple gingivitis, plaque-associated: Note: </b>Reserve systemic therapy for patients with rapidly progressive disease, severe pain, or immunocompromising conditions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 500 mg every 8 hours in combination with penicillin V for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Periodontitis, severe, plaque-associated:</b>
<b>Oral:</b> 500 mg every 8 hours in combination with amoxicillin for 14 days or until clinical resolution; use in addition to periodontal debridement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019','lexi-content-ref-29027242','lexi-content-ref-Wilder.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019','lexi-content-ref-29027242','lexi-content-ref-Wilder.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Pyogenic odontogenic soft tissue infection (alternative agent):</b>
<b>IV,</b>
<b>Oral:</b> 500 mg every 8 hours as part of an appropriate combination regimen until resolution, typically for 7 to 14 days. Use in addition to appropriate surgical management (eg, drainage and/or extraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Chow.2019','lexi-content-ref-Wilder.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Chow.2019','lexi-content-ref-Wilder.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c62274f1-4d80-4271-b954-8f3cc5a41178">Pneumonia, aspiration</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, aspiration (alternative agent):</b>
<b>Oral, IV:</b> 500 mg 3 times daily in combination with an appropriate beta-lactam (eg, oral amoxicillin, IV penicillin, or an IV third-generation cephalosporin) for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Klompas.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Klompas.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3488d7c-e7b9-412e-a573-cbcc83f5f171">Pouchitis, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pouchitis (post ileal pouch-anal anastomosis), acute (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Initial therapy (alternative agent): <b>Oral:</b> 500 mg every 12 hours for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19817675','lexi-content-ref-31785173','lexi-content-ref-11856075','lexi-content-ref-21775695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19817675','lexi-content-ref-31785173','lexi-content-ref-11856075','lexi-content-ref-21775695'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Refractory disease: <b>Oral:</b> 500 mg every 12 hours in combination with ciprofloxacin for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31333137','lexi-content-ref-Shen.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31333137','lexi-content-ref-Shen.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Empiric treatment following sexual assault in females (off-label use):</i> Oral:</b> 500 mg twice daily for 7 days, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Pelvic inflammatory disease:</i> Oral, IV:</b> 500 mg every 12 hours for 14 days as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Trichomoniasis (index case and sex partner):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Initial treatment:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Females: <b>Oral:</b> 500 mg twice daily for 7 days. <b>Note:</b> Single 2 g dose is less effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-27898571','lexi-content-ref-21423852','lexi-content-ref-30297322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-27898571','lexi-content-ref-21423852','lexi-content-ref-30297322'])">Ref</a></span>), but some experts suggest it as an alternative for those unlikely to complete a multiday regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sobel.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sobel.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Males: <b>Oral:</b> 2 g as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>). <b>Note:</b> Some experts suggest the multiday dosing used for females as an alternative regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sobel.2','lexi-content-ref-WHO.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sobel.2','lexi-content-ref-WHO.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Refractory infection: </i>
<b>Note:</b> Patients with suspected reinfection because of reexposure to an untreated partner may receive a regimen used for initial treatment. For others, clinicians may request a kit from the CDC to perform drug-resistance testing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral: </b>2 g once daily for 7 days. Alternatively, 500 mg twice daily for 7 days may be sufficient for patients with refractory infection following a single-dose regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Sobel.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Sobel.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Necrotizing infection (as a component of an appropriate combination regimen) (alternative agent): <b>IV:</b> 500 mg every 6 hours. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical site infection, incisional (eg, intestinal or GU tract; axilla or perineum), warranting anaerobic coverage: <b>IV:</b> 500 mg every 8 hours in combination with other appropriate agents. Duration depends on severity, need for debridement, and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 500 mg within 60 minutes prior to surgical incision in combination with other antibiotics. Considered a recommended agent for select procedures involving the GI tract, urologic tract, or head and neck (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Colorectal surgical prophylaxis (off-label use)</i>: 1 g every 3 to 4 hours for 3 doses with additional oral antibiotics, starting after mechanical bowel preparation the evening before a morning surgery and followed by an appropriate IV antibiotic prophylaxis regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Uterine evacuation (induced abortion or pregnancy loss) (alternative agent) (off-label use)</i>: 500 mg as a single dose 1 hour prior to uterine aspiration; may be administered up to 12 hours before the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29794678','lexi-content-ref-Shih.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29794678','lexi-content-ref-Shih.2018'])">Ref</a></span>). <b>Note:</b> The optimal dosing regimen has not been established; various protocols are in use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21397086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21397086'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="52f26aeb-8096-4aee-987a-92382ab5d9d0">Tetanus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tetanus (</b>
<i>
<b>Clostridium tetani</b></i>
<b> infection) (off-label use):</b>
<b>Oral, IV:</b> 500 mg every 6 to 8 hours for 7 to 10 days in combination with supportive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3928066','lexi-content-ref-Thwaites.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3928066','lexi-content-ref-Thwaites.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991130"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">Decreased kidney function does not impact serum half-life of metronidazole but is associated with accumulation of the active hydroxyl and almost inactive acetic acid metabolites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3731917','lexi-content-ref-3986078','lexi-content-ref-10384859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3731917','lexi-content-ref-3986078','lexi-content-ref-10384859'])">Ref</a></span>). Kidney dysfunction may confer a higher risk of CNS side effects, such as neuropathy, encephalopathy, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24257215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24257215'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Single-dose regimens (eg, 2 g once) do not require dose adjustment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥10 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>); however, monitor closely for adverse effects due to accumulation of metabolites in patients with more severe impairment (CrCl &lt;30 mL/minute), particularly with prolonged courses of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3731917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3731917'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>); however, monitor closely for adverse effects due to accumulation of metabolites, particularly with prolonged courses of therapy. A dose of 500 mg every 12 hours may be adequate to achieve therapeutic plasma levels for nonsevere non-<i>Clostridioides</i>
<i>difficile</i> infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6706889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6706889'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (42% to 65% metronidazole and hydroxyl and acetic acid metabolites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3717930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3717930'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral: </b>Usual dose: 500 mg every 8 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>). <b>Note:</b> Larger doses may be utilized depending on clinical indication, but with close monitoring for adverse effects, particularly if the treatment course is &gt;1 to 2 weeks in duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). On dialysis days, administer after dialysis. If administration cannot be separated from hemodialysis, consider supplemental dose following hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Minimally dialyzed (10% removal with single long dwell (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6660863','lexi-content-ref-6721462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6660863','lexi-content-ref-6721462'])">Ref</a></span>). Monitor for adverse effects due to metabolite accumulation, particularly if the treatment course is &gt;1 to 2 weeks in duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to metabolite accumulation is important:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations (eg, site of infection). Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Oral: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). On PIRRT days, administer after PIRRT session. If administration cannot be separated from PIRRT, consider supplemental dose following completion of PIRRT session.</p></div>
<div class="block doha drugH1Div" id="F50988462"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Metronidazole clearance is decreased and elimination half-life is prolonged in patients with cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7117899','lexi-content-ref-6423039','lexi-content-ref-10384859','lexi-content-ref-8703652']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7117899','lexi-content-ref-6423039','lexi-content-ref-10384859','lexi-content-ref-8703652'])">Ref</a></span>). Prolonged use or total cumulative dose may result in accumulation that has been linked to neurotoxicity and encephalopathy, which may be irreversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30536109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30536109'])">Ref</a></span>). Metronidazole-induced encephalopathy can usually be confirmed (~90% of cases) through MRI (eg, T2 weighted/coronal fluid-attenuated inversion recovery sequences demonstrating symmetric lesions of the dendritic nuclei) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30536109','lexi-content-ref-22870180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30536109','lexi-content-ref-22870180'])">Ref</a></span>). Close monitoring is warranted for early recognition of metronidazole-induced encephalopathy in patients with cirrhosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation: </b>Single-dose regimens (eg, 2 g once) do not require dose adjustment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A and B: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class C: Oral, IV: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Capsules: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Amebiasis:</b> 375 mg 3 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Trichomoniasis:</b> 375 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Injection, tablets: </b></p>
<p style="text-indent:-2em;margin-left:8em;">If usual recommended frequency is every 12 hours: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">If usual recommended frequency is every 6 to 8 hours: Maintain dose but reduce frequency to every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6423039','lexi-content-ref-3435113','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6423039','lexi-content-ref-3435113','lexi-content-ref-Expert.DOH'])">Ref</a></span>). For example, if usual recommended dose is 500 mg every 6 hours, then reduce to 500 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral suspension:</b> Reduce dose by 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55035892"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Metronidazole has been associated with a range of CNS effects, which include <b>peripheral neuropathy </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30120134','lexi-content-ref-28887203','lexi-content-ref-6307965']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30120134','lexi-content-ref-28887203','lexi-content-ref-6307965'])">Ref</a></span>), <b>aseptic meningitis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7893894','lexi-content-ref-17339628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7893894','lexi-content-ref-17339628'])">Ref</a></span>), <b>ataxia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23833378','lexi-content-ref-31736605']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23833378','lexi-content-ref-31736605'])">Ref</a></span>), <b>neuro</b>
<b>cerebellar toxicity</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27127600','lexi-content-ref-19915830','lexi-content-ref-21996645','lexi-content-ref-18511323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27127600','lexi-content-ref-19915830','lexi-content-ref-21996645','lexi-content-ref-18511323'])">Ref</a></span>), <b>confusion </b>or disorientation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21996645','lexi-content-ref-12642754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21996645','lexi-content-ref-12642754'])">Ref</a></span>),<b> dysarthria </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28198344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28198344'])">Ref</a></span>), <b>encephalopathy </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31692663','lexi-content-ref-27504340','lexi-content-ref-30536109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31692663','lexi-content-ref-27504340','lexi-content-ref-30536109'])">Ref</a></span>), <b>seizures </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22879116','lexi-content-ref-21996645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22879116','lexi-content-ref-21996645'])">Ref</a></span>), <b>optic neuropathy</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17760644','lexi-content-ref-1957918']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17760644','lexi-content-ref-1957918'])">Ref</a></span>), and <b>vertigo</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24296060','lexi-content-ref-22879116']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24296060','lexi-content-ref-22879116'])">Ref</a></span>). Most reports have occurred in adults; however, there are reports in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21996645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21996645'])">Ref</a></span>). CNS effects are generally reversible within days to weeks of discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30536109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30536109'])">Ref</a></span>); however, some cases may not be reversible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25561434']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25561434'])">Ref</a></span>). Peripheral neuropathy symptoms may be prolonged after discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unclear; proposed mechanisms include binding to neural RNA inhibiting protein synthesis, modulation of inhibitory neurotransmitters gamma-aminobutyric acid receptors within the cerebellar and vestibular systems, reversible mitochondrial dysfunction, and vasogenic and cytotoxic edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21996645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21996645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; median of 28 days was reported in a systematic review of metronidazole-induced encephalopathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30536109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30536109'])">Ref</a></span>) and a median of 54 days was reported in another systematic review (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21996645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21996645'])">Ref</a></span>); however, both reviews reported that some cases took less than a week.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b></b>May include:</p>
<p style="text-indent:-2em;margin-left:8em;">• High doses, high cumulative doses, or prolonged or repeated courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6829642','lexi-content-ref-7084034','lexi-content-ref-10761537','lexi-content-ref-21996645','lexi-content-ref-29462280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6829642','lexi-content-ref-7084034','lexi-content-ref-10761537','lexi-content-ref-21996645','lexi-content-ref-29462280'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Disulfiram-like reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited cases of <b>disulfiram-like reactions</b> with metronidazole have been reported in both adult and pediatric patients when used concurrently with alcohol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31598109','lexi-content-ref-8947362','lexi-content-ref-3492326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31598109','lexi-content-ref-8947362','lexi-content-ref-3492326'])">Ref</a></span>). Available clinical data demonstrating an association are conflicting and the CDC sexually transmitted infections guidelines state that refraining from alcohol use during metronidazole therapy is unnecessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-31871085','lexi-content-ref-10676835']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-31871085','lexi-content-ref-10676835'])">Ref</a></span>). The proposed mechanism of disulfiram-like reactions is inhibition of aldehyde dehydrogenase, which results in the accumulation of aldehydes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12022894']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12022894'])">Ref</a></span>). In one case report, onset was rapid, occurring after 2 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31598109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31598109'])">Ref</a></span>). No risk factors have been identified.</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F8771037"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (10% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginitis (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4%), diarrhea (4%), metallic taste (9%), xerostomia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysmenorrhea (3%), genital pruritus (5%), urinary tract infection (2%), urine abnormality (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Bacterial infection (7%), candidiasis (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (6%), pharyngitis (3%), rhinitis (4%), sinusitis (3%), upper respiratory tract infection (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, flattened T-wave on ECG, flushing, palpitations, peripheral edema, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythematous rash, hyperhidrosis, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, anorexia, constipation, decreased appetite, dysgeusia, epigastric discomfort, glossitis, hairy tongue, proctitis, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis, dyspareunia, dysuria, urinary incontinence, vaginal dryness, vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site, injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, chills, depression, drowsiness, hypoesthesia, insomnia, irritability, malaise, numbness, psychosis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal eye movements (saccadic), nystagmus disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, nasal congestion</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (Gnanapandithan 2021; Mojadidi 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, bullous dermatitis, fixed drug eruption, Stevens-Johnson syndrome (Mazumdar 2014), toxic epidermal necrolysis (Ali 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (O’Halloran 2010; Yilmaz 2016; Youssef 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration (Anjum 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (Taylor 1965), neutropenia (Khan 2008), thrombocytopenia (Lew 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure (especially in Cockayne syndrome) (Ataee 2020), hepatotoxicity (including severe hepatotoxicity, especially in Cockayne syndrome) (Hestin 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Asensio Sánchez 2008), drug reaction with eosinophilia and systemic symptoms, serum sickness-like reaction (joint pains) (VanCleave 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis (Khan 2007), ataxia (Sagvekar 2019), confusion (Kuriyama 2011), dysarthria (Boot 2017), encephalopathy (Roy 2016), mania (Puri 2021), neurocerebellar toxicity (Patel 2008), paresthesia (Soh 2021), peripheral neuropathy (Goolsby 2018), seizure (Huang 2012), vertigo (Chen 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuropathy (Chen 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Disulfiram-like reaction (with alcohol) (Alonzo 2019)</p></div>
<div class="block coi drugH1Div" id="F8771023"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component of the formulation; during the first trimester of pregnancy in patients with trichomoniasis (with the exception of Likmez); use of disulfiram within the past 2 weeks; use of alcohol or propylene glycol-containing products during therapy or within 3 days of therapy discontinuation; Cockayne syndrome.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the manufacturer’s labeling lists use of alcohol-containing products during therapy or within 3 days of therapy discontinuation as a contraindication, the CDC sexually transmitted infection guidelines state refraining from alcohol use while taking metronidazole is not necessary (CDC [Workowski 2021]). Clinical data demonstrating an association between concomitant use with alcohol and a disulfiram-like reaction are conflicting (Mergenhagen 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Active neurological disorders; history of blood dyscrasia; hypothyroidism; hypoadrenalism.</p></div>
<div class="block war drugH1Div" id="F8771024"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment due to potential accumulation; dosage adjustment recommended in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment due to potential accumulation; dosage adjustments may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage-form specific issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Use injection with caution in patients with heart failure, edema, or other sodium-retaining states, including corticosteroid treatment due to high sodium content. In patients receiving continuous nasogastric secretion aspiration, sufficient metronidazole may be removed in the aspirate to cause a reduction in serum levels.</p></div>
<div class="block dosfc drugH1Div" id="F26841822"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral solution contains 28 mEq of sodium/gram of metronidazole.</p>
<p style="text-indent:-2em;margin-left:2em;">First-Metronidazole oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>
<div class="block foc drugH1Div" id="F8771210"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flagyl: 375 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 375 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (100 mL); 500 mg/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (100 mL); 500 mg/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Likmez: 500 mg/5 mL (200 mL) [contains methylparaben, propylparaben; strawberry peppermint flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flagyl: 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F8770972"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8771212"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Flagyl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">375 mg (per each): $7.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (metroNIDAZOLE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">375 mg (per each): $12.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (metroNIDAZOLE Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/100 mL (per mL): $0.01 - $0.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Likmez Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $3.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (metroNIDAZOLE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.43 - $0.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.73 - $0.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869242"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Flagyl: 500 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block exp drugH1Div" id="F8771213"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> A metronidazole suspension is commercially available as 500 mg/5 mL (200 mL bottle) as well as 50 mg/mL or 100 mg/mL compounding kit.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>50 mg/mL Oral Suspension (ASHP Standard Concentration) (ASHP 2017)</b></p>
<p style="text-indent:-2em;margin-left:2em;">A 50 mg/mL oral suspension may be made with tablets and a 1:1 mixture of Ora-Sweet and Ora-Plus. Crush twenty-four 250 mg tablets in a mortar and reduce to a fine powder. Add small portions of the vehicle and mix to a uniform paste; mix while adding the vehicle in incremental portions to <b>almost</b> 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label "shake well". Stable for 60 days at room temperature or refrigerated (Allen 1996).</p>
<div class="reference">Allen LV Jr, Erickson MA 3rd. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53(17):2073-2078.<span class="pubmed-id">8870895</span></div>
</div>
<div class="block admp drugH1Div" id="F52614374"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer with food to minimize GI upset.</p>
<p style="text-indent:-2em;margin-left:4em;">Suspension: Shake well before use. Administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Administer undiluted (5 mg/mL) by slow intermittent infusion over 30 to 60 minutes. Avoid contact of drug solution with equipment containing aluminum.</p></div>
<div class="block adm drugH1Div" id="F8771184"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse intravenously over 30 to 60 minutes. Avoid contact of drug solution with equipment containing aluminum.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with food to minimize stomach upset. Shake suspension well before use; administer with an accurate measuring device (calibrated oral syringe or measuring cup); do not use a household teaspoon or tablespoon to measure dose.</p></div>
<div class="block sts drugH1Div" id="F8771125"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule, tablet: Store at 15°C to 25°C (59°F to 77°F). Protect the tablets from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 20°C to 25°C (68°F to 77°F). Protect from light. Avoid excessive heat. Do not refrigerate. Do not remove unit from overwrap until ready for use. Discard unused solution.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral suspension: Store at 20°C to 25°C (68°F to 77°F); excursion permitted between 15°C to 30°C (59°F to 86°F). Do not freeze. Discard any unused suspension 10 days after first opening.</p></div>
<div class="block usep drugH1Div" id="F53570638"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of amebiasis (intestinal [dysentery] or liver abscess) (FDA approved in pediatric patients [age not specified] and adults); treatment of susceptible anaerobic bacterial and protozoal infections in the following conditions: Symptomatic and asymptomatic trichomoniasis; skin and skin structure infections, bone and joint infections, CNS infections, endocarditis, gynecological infections, bacteremia, intra-abdominal infections, and lower respiratory tract infections (FDA approved in adults); has also been used for treatment of small intestinal bacterial overgrowth, peritonitis, and exit site or tunnel infections in patients with peritoneal dialysis catheters.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of susceptible anaerobic bacteria in the following conditions: Skin and skin structure infections, bone and joint infections, CNS infections, endocarditis, gynecological infections, bacteremia, intra-abdominal infections, and respiratory tract (lower) infections; surgical prophylaxis (colorectal) (All indications: FDA approved in adults); has also been used in the prophylaxis of peritonitis in patients with peritoneal dialysis catheters undergoing gastrointestinal or genitourinary procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used for treatment of giardiasis, pelvic inflammatory disease, tetanus, <i>Helicobacter pylori</i>, <i>Clostridioides</i>
<i>difficile</i> infection, and inflammatory bowel disease.</p></div>
<div class="block mst drugH1Div" id="F8770967"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MetroNIDAZOLE may be confused with mebendazole, meropenem, metFORMIN, methotrexate, metoclopramide, miconazole.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F8771042"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>
<div class="block dri drugH1Div" id="F8771043"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Busulfan: MetroNIDAZOLE (Systemic) may increase the serum concentration of Busulfan.  Management: Avoid coadministration metronidazole and busulfan due to increased risks of busulfan toxicity.  If coadministration is required, monitor busulfan concentrations closely and adjust the busulfan dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbocisteine: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, metronidazole may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). In particular, the risk for CNS toxicities such as psychosis may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of DroNABinol. Specifically, metronidazole may produce severe intolerance to the alcohol contained in the dronabinol oral solution. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: MetroNIDAZOLE (Systemic) may increase the serum concentration of Fluorouracil Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lithium. MetroNIDAZOLE (Systemic) may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lopinavir. Specifically, the combination of metronidazole and lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-like reaction. MetroNIDAZOLE (Systemic) may enhance the arrhythmogenic effect of Lopinavir.  Management: Avoid the concomitant use of lopinavir/ritonavir and metronidazole if possible. If these agents are used concomitantly, monitor for QTc prolongation/arrhythmia and if the lopinavir/ritonavir solution is used, development of a disulfiram-like reaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: MetroNIDAZOLE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of PHENobarbital. A disulfiram-like reaction may occur if combined with phenobarbital dosage forms that contain propylene glycol or alcohol. PHENobarbital may decrease the serum concentration of MetroNIDAZOLE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Phenytoin. A disulfiram-like reaction may occur if combined with phenytoin dosage forms that contain propylene glycol. Phenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of MetroNIDAZOLE (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Products Containing Propylene Glycol: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Products Containing Propylene Glycol. A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Specifically, the combination of ritonavir oral solution or ritonavir soft gelatin capsule, both of which contain alcohol, and metronidazole may result in a disulfiram-like reaction.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: CYP2C9 Inhibitors (Weak) may increase the serum concentration of TOLBUTamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vecuronium: MetroNIDAZOLE (Systemic) may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives to concomitant therapy with these agents.  If concomitant therapy cannot be avoided, consider reducing the dose of the vitamin K antagonist and monitor for increased INR/bleeding.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F8771047"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected.</p></div>
<div class="block dic drugH1Div" id="F8771183"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Take with food to minimize stomach upset.</p>
<p style="text-indent:-2em;margin-left:2em;">Sodium: Injectable dosage form may contain sodium.</p>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: According to the manufacturer’s labeling, use of ethanol is contraindicated during therapy and for 3 days after therapy discontinuation; however, the CDC sexually transmitted infection guidelines state refraining from alcohol use while taking metronidazole is not necessary (CDC [Workowski 2021]). Clinical data demonstrating an association between concomitant use with alcohol and a disulfiram-like reaction are conflicting (Mergenhagen 2020).</p></div>
<div class="block pri drugH1Div" id="F8771019"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Metronidazole crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Cleft lip with or without cleft palate has been reported following first trimester exposure to metronidazole; however, most studies have not shown an increased risk of congenital anomalies or other adverse events to the fetus following maternal use during pregnancy. Because metronidazole was carcinogenic in some animal species, concern has been raised whether metronidazole should be used during pregnancy. Available studies have not shown an increased risk of infant cancer following metronidazole exposure during pregnancy; however, the ability to detect a signal for this may have been limited.</p>
<p style="text-indent:0em;margin-top:2em;">Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Bacterial vaginosis and vaginal trichomoniasis are associated with adverse pregnancy outcomes (such as premature rupture of membranes, preterm delivery). The CDC recommends treatment of pregnant patients with symptomatic bacterial vaginosis; the twice daily dose of oral metronidazole for the treatment of bacterial vaginosis is the same for nonpregnant and pregnant patients; however, a three times daily regimen has also been used. Treatment of pregnant patients with asymptomatic bacterial vaginitis who are at high risk for preterm delivery has had mixed results. Metronidazole is also recommended for the treatment of vaginal trichomoniasis in pregnant patients. Although use of oral metronidazole for vaginal trichomoniasis during the first trimester is contraindicated by the manufacturer, available guidelines note treatment can be given at any stage of pregnancy (CDC [Workowski 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Metronidazole may also be used for the treatment of giardiasis in pregnant patients (some sources recommend second and third trimester administration only) (Gardner 2001; HHS [OI adult 2020]) and symptomatic amebiasis during pregnancy (HHS [OI adult 2020]; Li 1996). Short courses may be used for the treatment of pouchitis or perianal disease in pregnant patients with inflammatory bowel disease; not recommended for planned maintenance therapy (Mahadevan 2019). The use of other agents is preferred when treatment is needed for <i>Clostridioides</i>
<i>difficile </i>during pregnancy (ACG [Kelly 2021]). Consult current recommendations for appropriate use in pregnant patients.</p></div>
<div class="block mopp drugH1Div" id="F53570623"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor CBC with differential at baseline, during, and after prolonged or repeated courses of therapy. Monitor LFTs in patients with Cockayne syndrome. Closely monitor patients with severe hepatic impairment or ESRD for adverse reactions. Observe patients carefully if neurologic symptoms occur and consider discontinuation of therapy.</p></div>
<div class="block pha drugH1Div" id="F8771129"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">After diffusing into the organism, interacts with DNA to cause a loss of helical DNA structure and strand breakage resulting in inhibition of protein synthesis and cell death in susceptible organisms</p></div>
<div class="block phk drugH1Div" id="F8771131"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: To bile, seminal fluid, bone, liver, and liver abscesses, lung and vaginal secretions; crosses blood-brain barrier; saliva and CSF concentrations similar to those in plasma.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates (PMA: 24 to 39 weeks): Median: 0.95 L/kg (range: 0.75 to 1.03 L/kg) (Cohen-Wolkowiez 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥9 years and Adolescents ≤14 years: 0.64 ± 0.18 L/kg (Amon 1983).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &lt;20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (30% to 60%) to several metabolites including an active hydroxyl metabolite which maintains activity ~30% to 65% of the parent compound (Lamp 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates &lt;7 days (Jager-Roman 1982): Within first week of life, more prolonged with lower GA:</p>
<p style="text-indent:-2em;margin-left:6em;">GA 28 to 30 weeks: 75.3 ± 16.9 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 32 to 35 weeks: 35.4 ± 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 36 to 40 weeks: 24.8 ± 1.6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates ≥7 days: ~22.5 hours (Upadhyaya 1988).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: 6 to 10 hours (Lamp 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: Capsules, tablets: 1 to 2 hours; oral suspension: 0.25 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (unchanged drug and metabolites: 60% to 80%; ~20% of total as unchanged drug); feces (6% to 15%).</p></div>
<div class="block phksp drugH1Div" id="F51159555"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> CrCl ≤65 mL/minute: Half-life: 18 to 32 hours (hydroxy metabolite [active]) (Lamp 1999).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic function impairment:</b> Half-life: 18.31 hours (mean) in one study (Lau 1987).</p>
<p style="text-indent:-2em;margin-left:4em;">According to Child-Pugh classification (Muscara 1995):</p>
<p style="text-indent:-2em;margin-left:6em;">Child-Pugh class A: ~10.7 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Child-Pugh class B: ~13.5 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Child-Pugh class C: ~21.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-infective considerations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Concentration dependent; associated with total AUC<sub>24</sub>/minimum inhibitory concentration (MIC) (Craig 1998; Ibrahim 2004).</p>
<p style="text-indent:-2em;margin-left:6em;">Organism specific: <i>B. fragilis</i>: Goal: AUC/MIC ≥70 (Sprandel 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expected drug exposure in normal renal function:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>C<sub>max </sub>(peak): Single dose:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Neonates and Infants &lt;8 weeks PNA: IV: 20 mg/kg: 17.7 ± 3.1 mg/L (Rubenson 1986).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants 3 to 10 months of age: IV: 20 mg/kg: 25.3 ± 4.5 mg/L (Rubenson 1986).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥4 years of age and Adolescents ≤17 years of age: IV: 30 mg/kg (maximum dose: Weight &lt;80 kg: 1,000 mg; Weight &gt;80 kg: 1,500 mg): ~50 mg/L (Child 2019).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: Oral:</p>
<p style="text-indent:-2em;margin-left:10em;">250 mg: 6 mg/L (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg: ~8 to 12 mg/L (Lamp 1999; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:10em;">2 g: 40 mg/L (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>C<sub>max </sub>(peak): Steady state:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Preterm Neonates (GA ≤32 weeks; PNA ≤90 days): IV: 15 mg/kg loading dose followed by 7.5 mg/kg every 12 hours (PNA &lt;14 days) or 24 hours (PNA ≥14 days): 24.6 mg/L (Cohen-Wolkowiez 2013).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: IV:</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg every 8 hours: 22.2 ± 5 mg/L (Sprandel 2004).</p>
<p style="text-indent:-2em;margin-left:10em;">1 g once daily: 24.8 ± 6.8 mg/L (Sprandel 2004).</p>
<p style="text-indent:-2em;margin-left:10em;">1.5 g once daily: 37.7 ± 10 mg/L (Sprandel 2004).</p>
<p style="text-indent:-2em;margin-left:10em;">15 mg/kg loading dose; 7.5 mg/kg every 6 hours: 25 mg/L (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>AUC<sub>0-24 </sub>(total): Single dose:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥4 years of age and Adolescents ≤17 years of age (Child 2019): IV: 30 mg/kg (maximum dose: Weight &lt;80 kg: 1,000 mg; Weight &gt;80 kg: 1,500 mg):</p>
<p style="text-indent:-2em;margin-left:10em;">4 to 5 years of age: 612 to 732 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">6 to 9 years of age: 520 to 588 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">10 to 12 years of age: 419 to 478 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:10em;">13 to 17 years of age: 313 to 369 mg•hour/L.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>AUC<sub>0-24 </sub>(total): Steady state:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Adults: IV:</p>
<p style="text-indent:-2em;margin-left:10em;">500 mg every 8 hours: 356 ± 68 mg•hour/L (Sprandel 2004).</p>
<p style="text-indent:-2em;margin-left:10em;">1 g once daily: 227 ± 57 mg•hour/L (Sprandel 2004).</p>
<p style="text-indent:-2em;margin-left:10em;">1.5 g once daily: 338 ± 105 mg•hour/L (Sprandel 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Varies based on the organism and antimicrobial exposure (concentration and duration):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>C. difficile:</i> 1<i>.</i>2 to 1.7 hours (Odenholt 2007).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>T. vaginalis: </i>~6 hours (Nix 1995).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961987"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Elyzol | Flagyl | Flazole | Metrolag | Neogyl | Nidazol | Riazole | Supplin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Armax | Bexon | Dinestal | Fada metronidazol | Flagyl | Format | Ginkan | Metronidazol | Metronidazol apolo | Metronidazol biocrom | Metronidazol biol | Metronidazol fabra | Metronidazol lemax | Metronidazol richet | Metronidazol rivero 500 | Metronidazol vannier | Ovufem</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Anaerobex | Metronidazol | Metronidazol arcana | Metronidazol b braun | Metronidazol genericon pharma | Metronidazol kabi | Metronidazol Vioser | Metronidazol waldheim | Trichex</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazole juno | Metronidazole kabi | Metronidazole sandoz</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ametri | Amodis | Amotrex | Antipro | Anzole | Biozyl | Brimazol | Danidazol | Dirozyl | Filmet | Flagyl | Flamyd | G-metronidazole | Gyl | Kilpro | Librazol | M Zed | Menilet | Menol | Metason | Metonid | Metra | Metrion | Metro | Metrobac | Metrogyl | Metromax | Metryl | Neomet | Nidazyl | Onida | Prozol | Sb mezol | Servizol | Silmet</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Anaeromet | Flagyl</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Biozole | Metronidazole b braun</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Flagyl | Metris</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Canderm | Dazolston | Endonidazol | Flagyl | Fresenizol | Helmizol | Hidazol | Meflagin | Metrizol | Metronack | Metronidazol | Metroniflex | Nidazofarma | Odonid | Polibiotic | Tenaflox</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Arilin | Dumozol | Flagyl | Metronidazol B. Braun | Metronidazol mepha | Metronidazol zentiva | Metronidazole Bioren | Metronidazole vifor medical</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Biozole | Metrocare | Metrogyl | Midazole</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Benzoylmetronidazole | Jia er na | Jia le ning | Metronidazole and glucose | Ya zhou ning | Yi fu qing</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Mebicitrof | Metronidazol | Metrozin | Nirmet | Otrozol | Sermetrol | Tenaflox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Flagyl | Metronidazol | Metronidazole noridem</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Arilin | Clont | Flagyl | Fossyol | Infectoclont | Metronidazol | Metronidazol demo | Metronidazol Fresenius | Metronidazol noridem | Metronidazol saar | Vagimid</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazol Alpharma</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Etron | Format | Imilox | Metotrex | Metrex | Metro | Metroan | Metrocaps | Metrocol | Metronidazol | Metronidazol alfa | Midazole | Otrozol | Servizol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acromona | Amotein | Etron | Flagyl | Metronidazol | Nirmet | Otrozol | Servizol | Vetisol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Flagyl | Klion | Metronidazol | Metronidazol braun | Metronidazol nd | Metronidazol ns | Supplin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amrizole | Bumexazole | Copagaramon | Dumozol | Elyzol | Flagyl | Flazol | Metroflag | Trichogyl</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Amotein | Flagyl | Metronidazol aurovitas | Metronidazol braun | Metronidazol cepa | Metronidazol Diasa | Metronidazol G.E.S. | Metronidazol normon</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Metris | Metrogyl | Polgyl</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazol Claris | Metronidazole Vioser | Trikozol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazole arrow | Metronidazole baxter | Metronidazole bieffe | Metronidazole biogaran | Metronidazole dakota | Metronidazole fresenius | Metronidazole Lavoisier | Metronidazole merck | Metronidazole noridem | Metronidazole PCH</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Elyzol | Metrolyl | Metrovex | Metrozol | Zadstat</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Colpocin t | Flagyl | Gnostol | Metrogyl | Metronidazole cooper | Metronidazole/baxter | Metronidazole/Norma</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Frotin | Fuzuin | Metronil | Tolizole</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Medazol | Metronidazol B. Braun</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Klion | Metronidazol noridem | Metronidazol normon | Metronidazol teva | Metronidazol-human | Supplin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anmerob | Biatron | Dazolin | Diazole | Dimedazol | Dumozol | Elyzol | Farnat | Fladex | Flagyl | Fortagyl | Metrofusin | Metronidazole fresenius | Promuba | Rindozol | Robukil | Ronazol | Supplin | Trichodazol | Trogyl | Vadazol | Velazol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metrovex</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Flagyl</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aldezole | Altrogyl | Anaerid.s.i.v. | Aristogyl | Balgyl | Biozole | Flagyl | Flagyl er | Glucogyl | Lupigyl | Met | Metgyl | Metris | Metro | Metrocip | Metrogyl | Metrogyl er | Metrokem | Metron | Metronidazole &amp; dextrose | Premogyl | Rogyl | Unimezol | Wingyl | Wometro</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Flagyrol fort | Furazol forte | Metrobac | Safagyl</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Flagyl</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Deflamon | Metronidazolo | Metronidazolo Aurobindo | Metronidazolo Bbu | Metronidazolo bieffe medital | Metronidazolo bioindustria | Metronidazolo kabi | Metronidazolo salf | Vagilen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Colpocin t | Elyzol | Entogyl | Flagyl | Fungizol | Metrazine | Metrolag | Supplin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anaemetro | Asuzol | Flagyl | Kyometol | Meronidal | Metronidazole amel | Metronidazole merck hoei | Metronidazole nichiiko | Nida | Salandol | Sawagyl | Takimetol | Trichocide | Wagitran</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Abagyl | Axagyl | Biozole | Flagyl | Metlife | Metris | Metrocach | Metrogyl | Metrolag | Metrozol | Metzole | Nirmet | Trichazole | Trichogyl | Trogyl | Troz</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Baxter metronidazole | Flagyl | Inno.n metronidazol | Metazole | Metrinal | Trizele | Tronal</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Elyzol | Flagyl | Metronidazol | Metronidazole Braun | Mirazol | Neogyl | Supplin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metris | Metronidazole fresenius | Supplin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Arilin | Efloran | Flagyl | Klion | Metrogyl | Metronidasoli | Metronidazol | Metronidazol arena | Metronidazole Vioser | Metroxan | Supplin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazol</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Flagyl | Flazole | Klion | Metrogyl | Metronidazol | Metronidazole fresenius | Metronidazolum | Trikacide</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Zyrdol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amiyodazol | Flagenase | Flagyl | Flaxtec | Hasolmedel | Kabizol | Metronidazol | Metronidazol gi pi | Metronidazol rimsa | Metronidazol Tecnofarma | Otrozol | Servizol | Solsensi | Tenaflox | Vertisal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Frotin | Metagyl | Metrogyl | Metronidazole Pharmaniaga | Ranigyl</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Amrizole | Cedazole | Flagyl | Jugyl | Kinglion metronidazole | Metrolife | Nci metronidazole | Nelb metronidazole | Nirmet | Rebok metronidazole | St dennis metronidazole | Trimetro | Troz | Unigyl</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Elyzol | Flagyl | Metronidazol | Metronidazol Alpharma | Metronidazol aurobindo | Metronidazol noridem | Metronidazol pch</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Aft Metronidazole | Colpocin t | Flagyl</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Flagimed | Flagyl | Metrexol | Metronidazol | Metrostat | Metrozol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ailyzole | Altozol | Anerobia | Anerobizol | Antizoal | Astrozol | Axagyl | B braun metronidazole | Bacimex | Cetaz | Dazomet | Eastmezol | Elizol | Erzol | Flagyl | Frotin | Godazole | Hizon metronidazole | Imetron | Medizole | Metdazid | Metrazol | Metrinox | Metroclear | Metromax | Metromed | Metronidazol | Metronidazol Winthrop | Microzol | Moniliasol | Neorobic | Newmet | Nidazoprime | Nirmet | Norstene | Nozol | Onizole | Panazole | Patryl | Pharex metronidazole | Promeddazole | Protozole | Servizol | Triconex | Tridel | Trozodaz | Usa-metronidazole | Zol | Zolegyl | Zolemet | Zolvex</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Abozole | Amezole | Amorob | Anarob | Diazol | Diazole | Eflaran | Flagyl | Flagynase | Flazol | Flezole | Gee metro | Gramex | Inglee | Intobix | Klint | Livgyl | Lomet | Markgyl | Medigyl | Metason | Metical | Metrida | Metro | Metroate | Metrodan | Metrofit | Metrogyl | Metrolite | Metrome | Metrosol | Metrostat | Metrozil | Metrozine | Metwise | Metzeena | Metzin | Metzol | Mezole | Microgin | Mtz | Murazol | Narobe | Nidagyl | Opozol | Otsuzol | Palmizol | Protoxil | Prozyl | Resgyl | Revgyl | Saydazole | Sidazole | Trichozole | Troz | Zavad | Zonid</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Flagyl | Metronidazol | Metronidazol aurovitas | Metronidazol polpharma | Metronidazole b braun</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Flagyl er | Metronidazole</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dumozol | Metronidazol | Metronidazol basi | Metronidazol Generis | Metronidazol labesfal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Cariodent zol | Medazol | Metrobiot | Metronac | Metronidazol dutriec | Metronidazol halexistar | Metronidazol phi | Metronidazol prosalud | Metrosol | Tricolan | Tricoval</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Amrizole | Amrizole OS | Anazol | Apo-Metronidazole | Flagicure Forte | Flagyl | Flagyl S | Flanizol | Flazol | Fungizol | Metgyl | Metris | Metzol | Metzol-S | Negazole | Negazole OS | Neogyl | Nidazole | Nidazole OS | Riazole | Riazole OS | Supplin | Suprazole</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Klion | Metronidazol arena | Metronidazol Vioser</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alimezole | Aquametro | Bacimex | Edgil | Efloran | Flagyl | Klion | Metrogyl | Metrolacare | Metron | Metronidal | Metronidazole escom | Metronidazole nycomed | Nirmet | Trichasol | Trichopol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Elyzol | Flagyl | Mopizale | Nidazole | Riazole</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Metronidazol actavis | Metronidazol baxter | Metronidazol eql pharma | Metronidazol norcox | Metronidazole Braun</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Flagyl | Ranigyl</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Flagyl | Metronidazol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Klion | Metronidazol braun | Metronidazole noridem</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Bactozole</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Asiazole | Biogyl | Chanenidazole | Flagyl | Klion | Klont | Lidazole | Manodazole | Medazyl | Medizole | Mepagyl | Metrazole | Metrex | Metrogyl | Metrolex | Metron | Metronid | Metronidazole fresenius kabi | Metronidazole iv b braun | Metrovid | Metrowin | Mezole | Milanidazole | Mydazole | Nida zole | Nirmet | Novamet | Octec | Temonas | Trichobon | Tridazol | Vagil</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Anaeryl | Flagyl | Metrogyl | Metronidazol Biosedra | Metronidazole infomed | Nidazol | Protogyl | Protozol | Tamizol | Trichex</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Fladazol | Flagyl | Laronium | Metronidazol | Metrosel | Metrosol | Neofleks metronidazol | Nidazol | Polgyl</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anegyn | Antimonas | Arcazol | Chomozin | Chozine | Destrinalis | Flagyl | Frotin | Fulikan | Fulon | Fuzuin | Geel | Lifemiss | Medazole | Metoyui | Metricho | Metrocide | Metrodin | Metrole | Metron | Metrozole | Paurapol | Pynal | Sabs | Santon | Servizol | Terico-s | Tolizole | Tonilin | Tricogyl | Tricon</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Efloran | Flagyl | Klion | Metressa | Metrid | Metrogyl | Metroxan | Metrozol | Trikasaid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aartrogyl | Abgyl | Axagyl | Metlife | Metris | Metrogyl | Metron | Metroren fc | Metrozole | Nirmet | Zifamet</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dazolston | Flagyl | Ginplus | Metronidazol | Metronidazol Lazar | Noxidazol | Servizol | Setixol | Trimstat</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bactrizol | Flegyl | Metris | Metrocof | Metrogyl | Metronidazol | Metrovax | Metrowell | Metrozol</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Moretel</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bio metronidazole | Flagyl | Metagyl | Metris | Metronidazole b braun | Metronidazole fresenius | Narobic | Sabax metronidazole | Trichazole</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Flazole | Hecmetro 200 | Intramed trichazole | Metlife | Metris | Shalmet | Trichogyl</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Metris | Nirmet | Trichazole</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-21397086">
<a name="21397086"></a>Achilles SL, Reeves MF; Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. <i>Contraception</i>. 2011;83(4):295-309. doi:10.1016/j.contraception.2010.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21397086/pubmed" id="21397086" target="_blank">21397086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27127600">
<a name="27127600"></a>Agarwal A, Kanekar S, Sabat S, Thamburaj K. Metronidazole-induced cerebellar toxicity. <i>Neurol Int</i>. 2016;8(1):6365. doi:10.4081/ni.2016.6365<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27127600/pubmed" id="27127600" target="_blank">27127600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928066">
<a name="3928066"></a>Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. <i>Br Med J</i>. 1985;291(6496):648-650.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3928066/pubmed" id="3928066" target="_blank">3928066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34527487">
<a name="34527487"></a>Ali J, Rahman M, Ahmad A, Khattak Z, Shahzad MA. Toxic epidermal necrolysis secondary to metronidazole. <i>Cureus</i>. 2021;13(8):e17101. doi:10.7759/cureus.17101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/34527487/pubmed" id="34527487" target="_blank">34527487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allen.1">
<a name="Allen.1"></a>Allen LV Jr, Erickson MA 3rd. Stability of ketoconazole, metolazone, metronidazole, procainamide hydrochloride, and spironolactone in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53(17):2073-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31598109">
<a name="31598109"></a>Alonzo MM, Lewis TV, Miller JL. Disulfiram-like reaction with metronidazole: an unsuspected culprit. <i>J Pediatr Pharmacol Ther</i>. 2019;24(5):445-449. doi:10.5863/1551-6776-24.5.445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31598109/pubmed" id="31598109" target="_blank">31598109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6829642">
<a name="6829642"></a>Alvarez RS, Richardson DA, Bent AE, Ostergard DR. Central nervous system toxicity related to prolonged metronidazole therapy. <i>Am J Obstet Gynecol</i>. 1983;145(5):640-641. doi:10.1016/0002-9378(83)91214-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6829642/pubmed" id="6829642" target="_blank">6829642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812485">
<a name="23812485"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 135: Second-trimester abortion. <i>Obstet Gynecol</i>. 2013;121(6):1394-1406. doi:10.1097/01.AOG.0000431056.79334.cc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23812485/pubmed" id="23812485" target="_blank">23812485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794678">
<a name="29794678"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 195: Prevention of infection after gynecologic procedures. <i>Obstet Gynecol</i>. 2018;131(6):e172-e189. doi: 10.1097/AOG.0000000000002670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29794678/pubmed" id="29794678" target="_blank">29794678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7471904">
<a name="7471904"></a>Amon I, Amon K, Franke G, et al. Pharmacokinetics of metronidazole in pregnant women. <i>Chemotherapy</i>. 1981;27(2):73-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7471904/pubmed" id="7471904" target="_blank">7471904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6832193">
<a name="6832193"></a>Amon I, Amon K, Scharp H, Franke G, Nagel F. Disposition kinetics of metronidazole in children. <i>Eur J Clin Pharmacol</i>. 1983;24(1):113-119. doi:10.1007/BF00613937<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6832193/pubmed" id="6832193" target="_blank">6832193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12827655">
<a name="12827655"></a>Anagyrou K, Petrikkos GL, Suller MT, et al. Pulmonary Balantidium coli infection in a leukemic patient. <i>Am J Hematol</i>. 2003;73(3):180-183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/12827655/pubmed" id="12827655" target="_blank">12827655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36705176">
<a name="36705176"></a>Anjum MF, Twanabasu S, Shrestha K. Urine discoloration associated with metronidazole: a case report. <i>JNMA J Nepal Med Assoc</i>. 2022;60(255):972-974. doi:10.31729/jnma.7889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/36705176/pubmed" id="36705176" target="_blank">36705176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Arnoff.1">
<a name="Arnoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug prescribing in renal failure: dosing guidelines for adults and children. </i>5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18447147">
<a name="18447147"></a>Asensio Sánchez T, Dávila I, Moreno E, et al. Anaphylaxis due to metronidazole with positive skin prick test. <i>J Investig Allergol Clin Immunol</i>. 2008;18(2):138-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18447147/pubmed" id="18447147" target="_blank">18447147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32082677">
<a name="32082677"></a>Ataee P, Karimi A, Eftekhari K. Hepatic failure following metronidazole in children with Cockayne syndrome. <i>Case Rep Pediatr</i>. 2020;2020:9634196. doi:10.1155/2020/9634196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/32082677/pubmed" id="32082677" target="_blank">32082677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019a">
<a name="Baddour.2019a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019b">
<a name="Baddour.2019b"></a>Baddour LM, Harper M. Human bites: Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barshak.2018">
<a name="Barshak.2018"></a>Barshak MB. Antimicrobial approach to intra-abdominal infections in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bartelt.2018">
<a name="Bartelt.2018"></a>Bartelt LA. Giardiasis: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Beigi.2018">
<a name="Beigi.2018"></a>Beigi RH. Management and complications of tubo-ovarian abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23686128">
<a name="23686128"></a>Bellanger AP, Scherer E, Cazorla A, Grenouillet F. Dysenteric syndrome due to Balantidium coli: a case report. <i>New Microbiol</i>. 2013;36(2):203-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23686128/pubmed" id="23686128" target="_blank">23686128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31333137">
<a name="31333137"></a>Benlice C, Shen B, Steele SR. Prevention and medical treatment of pouchitis in ulcerative colitis. <i>Curr Drug Targets</i>. 2019;20(13):1399-1408. doi:10.2174/1389450120666190723130137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31333137/pubmed" id="31333137" target="_blank">31333137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3731917">
<a name="3731917"></a>Bergan T, Thorsteinsson SB. Pharmacokinetics of metronidazole and its metabolites in reduced renal function. <i>Chemotherapy</i>. 1986;32(4):305-318. doi:10.1159/000238429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3731917/pubmed" id="3731917" target="_blank">3731917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35203881">
<a name="35203881"></a>Bianchini S, Rigotti E, Monaco S, et al. Surgical antimicrobial prophylaxis in abdominal surgery for neonates and paediatrics: a RAND/UCLA appropriateness method consensus study. <i>Antibiotics (Basel)</i>. 2022;11(2):279. doi:10.3390/antibiotics11020279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/35203881/pubmed" id="35203881" target="_blank">35203881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bitton.2019">
<a name="Bitton.2019"></a>Bitton A, Fichera A. Perianal Crohn disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29909695">
<a name="29909695"></a>Bodilsen J, Brouwer MC, Nielsen H, Van De Beek D. Anti-infective treatment of brain abscess. <i>Expert Rev Anti Infect Ther</i>. 2018;16(7):565-578. doi: 10.1080/14787210.2018.1489722.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29909695/pubmed" id="29909695" target="_blank">29909695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21701406">
<a name="21701406"></a>Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(6):646-650. doi:10.1097/MPG.0b013e318229c769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21701406/pubmed" id="21701406" target="_blank">21701406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28198344">
<a name="28198344"></a>Boot EM, Hanny KH, Meijer FJ, van Eijk JJ. Een vrouw met reversibele encefalopathie [A woman with reversible encephalopathy]. Article in Dutch. <i>Ned Tijdschr Geneeskd</i>. 2017;161:D690.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28198344/pubmed" id="28198344" target="_blank">28198344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.3">
<a name="Bradley.3"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 29th ed. American Academy of Pediatrics; 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al; American Society of Health-System Pharmacists; Infectious Diseases Society of America; Surgical Infection Society; Society for Healthcare Epidemiology of America. Clinical practice guidelines for antimicrobial prophylaxis in surgery. <i>Am J Health Syst Pharm.</i> 2013;70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28653787">
<a name="28653787"></a>Butenko T, Jeverica S, Orel R, Homan M. Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children. <i>Helicobacter</i>. 2017;22(5):e12400. doi:10.1111/hel.12400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28653787/pubmed" id="28653787" target="_blank">28653787</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6660863">
<a name="6660863"></a>Cassey JG, Clark DA, Merrick P, Jones B. Pharmacokinetics of metronidazole in patients undergoing peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 1983;24(6):950-951. doi:10.1128/aac.24.6.950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6660863/pubmed" id="6660863" target="_blank">6660863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29926946">
<a name="29926946"></a>Caton JG, Armitage G, Berglundh T, et al. A new classification scheme for periodontal and peri-implant diseases and conditions - introduction and key changes from the 1999 classification. <i>J Periodontol</i>. 2018;89(suppl 1):S1-S8. doi: 10.1002/JPER.18-0157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29926946/pubmed" id="29926946" target="_blank">29926946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22874837">
<a name="22874837"></a>Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(31):590-594.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22874837/pubmed" id="22874837" target="_blank">22874837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Parasites – Dientamoeba fragilis: Resources for Health Professionals. <a href="https://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html" target="_blank">http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html</a>. Updated December 12, 2012. Accessed April 10, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2013">
<a name="CDC.2013"></a>Centers for Disease Control and Prevention (CDC). Parasites – Balantidiasis: Resources for Health Professionals. <a href="https://www.cdc.gov/parasites/balantidium/health_professionals/index.html" target="_blank">https://www.cdc.gov/parasites/balantidium/health_professionals/index.html</a>. Updated May 20, 2020. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19915830">
<a name="19915830"></a>Chatzkel JA, Vossough A. Metronidazole-induced cerebellar toxicity. <i>Pediatr Radiol</i>. 2010;40(8):1453. doi:10.1007/s00247-009-1453-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/19915830/pubmed" id="19915830" target="_blank">19915830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24296060">
<a name="24296060"></a>Chen PS, Huang JK, Cheng SJ, Lin HC. Metronidazole-induced vertigo. <i>Kaohsiung J Med Sci</i>. 2013;29(12):695-696. doi:10.1016/j.kjms.2013.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/24296060/pubmed" id="24296060" target="_blank">24296060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection [published correction appears in <i>Am J Gastroenterol</i>. 2018;113(7):1102]. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi:10.1038/ajg.2016.563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong B. American College of Gastroenterology guideline on the management of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2007;102(8):1808-1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29788329">
<a name="29788329"></a>Child J, Chen X, Mistry RD, et al. Pharmacokinetic and pharmacodynamic properties of metronidazole in pediatric patients with acute appendicitis: a prospective study. <i>J Pediatric Infect Dis Soc</i>. 2019;8(4):297-302. doi:10.1093/jpids/piy040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29788329/pubmed" id="29788329" target="_blank">29788329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18042954">
<a name="18042954"></a>Ching YA, Gura K, Modi B, Jaksic T. Pediatric intestinal failure: nutrition, pharmacologic, and surgical approaches. <i>Nutr Clin Pract</i>. 2007;22(6):653-663. doi:10.1177/0115426507022006653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18042954/pubmed" id="18042954" target="_blank">18042954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chow.2019">
<a name="Chow.2019"></a>Chow AW. Complications, diagnosis, and treatment of odontogenic infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8947362">
<a name="8947362"></a>Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ethanol interaction. <i>Am J Forensic Med Pathol</i>. 1996;17(4):343-346. doi:10.1097/00000433-199612000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/8947362/pubmed" id="8947362" target="_blank">8947362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22252819">
<a name="22252819"></a>Cohen-Wolkowiez M, Ouellet D, Smith PB, et al. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. <i>Antimicrob Agents Chemother</i>. 2012;56(4):1828-1837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22252819/pubmed" id="22252819" target="_blank">22252819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23587979">
<a name="23587979"></a>Cohen-Wolkowiez M, Sampson M, Bloom BT, et al. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. <i>Pediatr Infect Dis J</i>. 2013;32(9):956-961.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23587979/pubmed" id="23587979" target="_blank">23587979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32453198">
<a name="32453198"></a>Commander SJ, Gao J, Zinkhan EK, et al. Safety of metronidazole in late pre-term and term infants with complicated intra-abdominal infections. <i>Pediatr Infect Dis J</i>. 2020;39(9):e245-e248. doi:10.1097/INF.0000000000002698<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/32453198/pubmed" id="32453198" target="_blank">32453198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7893894">
<a name="7893894"></a>Corson AP, Chretien JH. Metronidazole-associated aseptic meningitis. <i>Clin Infect Dis</i>. 1994;19(5):974. doi:10.1093/clinids/19.5.974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7893894/pubmed" id="7893894" target="_blank">7893894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. <i>Clin Infect Dis</i>. 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18727929">
<a name="18727929"></a>D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. <i>Gastroenterology</i>. 2008;135(4):1123-1129. doi:10.1053/j.gastro.2008.07.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18727929/pubmed" id="18727929" target="_blank">18727929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7117899">
<a name="7117899"></a>Daneshmend TK, Homeida M, Kaye CM, Elamin AA, Roberts CJ. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. <i>Gut</i>. 1982;23(10):807-813. doi:10.1136/gut.23.10.807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7117899/pubmed" id="7117899" target="_blank">7117899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25542620">
<a name="25542620"></a>De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. <i>Lancet</i>. 2015;385(9976):1406-1417. doi:10.1016/S0140-6736(14)61908-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/25542620/pubmed" id="25542620" target="_blank">25542620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36669519">
<a name="36669519"></a>de Wijkerslooth EML, Boerma EG, van Rossem CC, et al; APPIC Study Group. 2 days versus 5 days of postoperative antibiotics for complex appendicitis: a pragmatic, open-label, multicentre, non-inferiority randomised trial.<i> Lancet</i>. 2023;401(10374):366-376. doi:10.1016/S0140-6736(22)02588-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/36669519/pubmed" id="36669519" target="_blank">36669519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30664553">
<a name="30664553"></a>Desai M, Fathallah J, Nutalapati V, Saligram S. Antibiotics versus no antibiotics for acute uncomplicated diverticulitis: a systematic review and meta-analysis. <i>Dis Colon Rectum</i>. 2019;62(8):1005-1012. doi:10.1097/DCR.0000000000001324<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/30664553/pubmed" id="30664553" target="_blank">30664553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30120134">
<a name="30120134"></a>Diodato D, Olivieri G, Pro S, et al. Axonal peripheral neuropathy in propionic acidemia: a severe side effect of long-term metronidazole therapy. <i>Neurology</i>. 2018;91(12):565-567. doi:10.1212/WNL.0000000000006209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/30120134/pubmed" id="30120134" target="_blank">30120134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DPI.1">
<a name="DPI.1"></a>Drugs for Parasitic Infections. <i>Treat Guidel Med Lett.</i> 2013;11(suppl):e1-e31.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3492326">
<a name="3492326"></a>Edwards DL, Fink PC, Van Dyke PO. Disulfiram-like reaction associated with intravenous trimethoprim-sulfamethoxazole and metronidazole. <i>Clin Pharm</i>. 1986;5(12):999-1000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3492326/pubmed" id="3492326" target="_blank">3492326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1860284">
<a name="1860284"></a>Eisenberg L, Suchow R, Coles RS, et al. The effects of metronidazole administration on clinical and microbiologic parameters of periodontal disease. <i>Clin Prev Dent.</i> 1991;13(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/1860284/pubmed" id="1860284" target="_blank">1860284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12596112">
<a name="12596112"></a>Emil S, Laberge JM, Mikhail P, et al. Appendicitis in children: a ten-year update of therapeutic recommendations. <i>J Pediatr Surg</i>. 2003;38(2):236-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/12596112/pubmed" id="12596112" target="_blank">12596112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7454176">
<a name="7454176"></a>Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. <i>Obstet Gynecol</i>. 1981;57(1):48-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7454176/pubmed" id="7454176" target="_blank">7454176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102658">
<a name="27102658"></a>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27102658/pubmed" id="27102658" target="_blank">27102658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423039">
<a name="6423039"></a>Farrell G, Zaluzny L, Baird-Lambert J, Cvejic M, Buchanan N. Impaired elimination of metronidazole in decompensated chronic liver disease. <i>Br Med J (Clin Res Ed).</i> 1983;287(6408):1845. doi:10.1136/bmj.287.6408.1845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6423039/pubmed" id="6423039" target="_blank">6423039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34051983">
<a name="34051983"></a>Feuerstein JD, Ho EY, Shmidt E, et al; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's Disease. <i>Gastroenterology</i>. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/34051983/pubmed" id="34051983" target="_blank">34051983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flagyl.1">
<a name="Flagyl.1"></a>Flagyl capsules (metronidazole) [prescribing information]. New York, NY: Pfizer Labs; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flagyl.2">
<a name="Flagyl.2"></a>Flagyl tablets (metronidazole) [prescribing information]. New York, NY: Pfizer Labs; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flagyl.3">
<a name="Flagyl.3"></a>Flagyl ER (metronidazole) [prescribing information]. New York, NY: Pfizer; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flagyl.4">
<a name="Flagyl.4"></a>Flagyl (metronidazole) [product monograph]. Toronto, Ontario, Canada: sanofi-aventis Canada Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20620320">
<a name="20620320"></a>Fraser JD, Aguayo P, Leys CM, et al. A complete course of intravenous antibiotics vs a combination of intravenous and oral antibiotics for perforated appendicitis in children: a prospective, randomized trial. <i>J Pediatr Surg</i>. 2010;45(6):1198-1202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20620320/pubmed" id="20620320" target="_blank">20620320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11148005">
<a name="11148005"></a>Gardner TB, Hill DR. Treatment of giardiasis. <i>Clin Microbiol Rev</i>. 2001;14(1):114-128. doi:10.1128/CMR.14.1.114-128.2001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/11148005/pubmed" id="11148005" target="_blank">11148005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29604616">
<a name="29604616"></a>Geballa-Koukoula A, Panderi I, Zervas K, et al. A porous graphitized carbon LC-ESI/MS method for the quantitation of metronidazole and fluconazole in breast milk and human plasma. <i>J Chromatogr B Analyt Technol Biomed Life Sci.</i> 2018;1084:175-184. doi:10.1016/j.jchromb.2018.03.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29604616/pubmed" id="29604616" target="_blank">29604616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33562182">
<a name="33562182"></a>Gnanapandithan K, Karthik N, Gerber J. Methadone, metoclopramide and metronidazole interaction causing Torsades de Pointes. <i>Clin Pract</i>. 2021;11(1):101-105. Published Feb 7, 2021. doi:10.3390/clinpract11010015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/33562182/pubmed" id="33562182" target="_blank">33562182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28887203">
<a name="28887203"></a>Goolsby TA, Jakeman B, Gaynes RP. Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature. <i>Int J Antimicrob Agents</i>. 2018;51(3):319-325. doi:10.1016/j.ijantimicag.2017.08.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28887203/pubmed" id="28887203" target="_blank">28887203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23235648">
<a name="23235648"></a>Granados CE, Reveiz L, Uribe LG, Criollo CP. Drugs for treating giardiasis. <i>Cochrane Database Syst Rev</i>. 2012;12(12):CD007787. doi:10.1002/14651858.CD007787.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23235648/pubmed" id="23235648" target="_blank">23235648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13901320">
<a name="13901320"></a>Gray MS, Kane PO, Squires S. Further observations on metronidazole (Flagyl). <i>Br J Vener Dis</i>. 1961;37:278-279. doi:10.1136/sti.37.4.278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/13901320/pubmed" id="13901320" target="_blank">13901320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6721462">
<a name="6721462"></a>Guay DR, Meatherall RC, Baxter H, Jacyk WR, Penner B. Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 1984;25(3):306-310. doi:10.1128/aac.25.3.306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6721462/pubmed" id="6721462" target="_blank">6721462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7084034">
<a name="7084034"></a>Halloran TJ. Convulsions associated with high cumulative doses of metronidazole. <i>Drug Intell Clin Pharm</i>. 1982;16(5):409. doi:10.1177/106002808201600511<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7084034/pubmed" id="7084034" target="_blank">7084034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23833378">
<a name="23833378"></a>Hari A, Srikanth BA, Lakshmi GS. Metronidazole induced cerebellar ataxia. <i>Indian J Pharmacol</i>. 2013;45(3):295-297. doi:10.4103/0253-7613.111903<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23833378/pubmed" id="23833378" target="_blank">23833378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27560034">
<a name="27560034"></a>Hazarika M, Pai H V, Khanna V, Reddy H, Tilak K, Chawla K. Rare case of polymicrobial keratitis with Balantidium coli. <i>Cornea</i>. 2016;35(12):1665-1667. doi:10.1097/ICO.0000000000000982<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27560034/pubmed" id="27560034" target="_blank">27560034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy.</i> 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6854509">
<a name="6854509"></a>Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mothers and infants. <i>J Perinat Med</i>. 1983; 11(2):114-120. doi:10.1515/jpme.1983.11.2.114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6854509/pubmed" id="6854509" target="_blank">6854509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7830880">
<a name="7830880"></a>Hestin D, Hanesse B, Frimat L, Trechot P, Netter P, Kessler M. Metronidazole-associated hepatotoxicity in a hemodialyzed patient. <i>Nephron</i>. 1994;68(2):286. doi:10.1159/000188282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7830880/pubmed" id="7830880" target="_blank">7830880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25561434">
<a name="25561434"></a>Hobbs K, Stern-Nezer S, Buckwalter MS, Fischbein N, Finley Caulfield A. Metronidazole-induced encephalopathy: not always a reversible situation. <i>Neurocrit Care</i>. 2015;22(3):429-436. doi:10.1007/s12028-014-0102-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/25561434/pubmed" id="25561434" target="_blank">25561434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3986078">
<a name="3986078"></a>Houghton GW, Dennis MJ, Gabriel R. Pharmacokinetics of metronidazole in patients with varying degrees of renal failure. <i>Br J Clin Pharmacol</i>. 1985;19(2):203-209. doi:10.1111/j.1365-2125.1985.tb02632.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3986078/pubmed" id="3986078" target="_blank">3986078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27898571">
<a name="27898571"></a>Howe K, Kissinger PJ. Single-dose compared with multidose metronidazole for the treatment of trichomoniasis in women: a meta-analysis. <i>Sex Transm Dis</i>. 2017;44(1):29-34. doi:10.1097/OLQ.0000000000000537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27898571/pubmed" id="27898571" target="_blank">27898571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22879116">
<a name="22879116"></a>Huang YT, Chen LA, Cheng SJ. Metronidazole-induced encephalopathy: case report and review literature. <i>Acta Neurol Taiwan</i>. 2012;21(2):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22879116/pubmed" id="22879116" target="_blank">22879116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117692">
<a name="24117692"></a>Huang J, Zhou L, Geng L, et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. <i>Aliment Pharmacol Ther</i>. 2013;38(10):1230-1235. doi:10.1111/apt.12516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/24117692/pubmed" id="24117692" target="_blank">24117692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26703242">
<a name="26703242"></a>Hurst AL, Olson D, Somme S, et al. Once-daily ceftriaxone plus metronidazole versus ertapenem and/or cefoxitin for pediatric appendicitis. <i>J Pediatric Infect Dis Soc</i>. 2017;6(1):57-64. doi:10.1093/jpids/piv082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/26703242/pubmed" id="26703242" target="_blank">26703242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15504841">
<a name="15504841"></a>Ibrahim KH, Gunderson BW, Hermsen ED, Hovde LB, Rotschafer JC. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron. <i>Antimicrob Agents Chemother.</i> 2004;48(11):4195-4199. doi:10.1128/AAC.48.11.4195-4199.2004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/15504841/pubmed" id="15504841" target="_blank">15504841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-922400">
<a name="922400"></a>Ingham HR, Slekon JB, Roxby CM. Bacteriological study of otogenic cerebral abscesses: chemotherapeutic role of metronidazole. <i>Br Med J</i>. 1977;2(6093):991-993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/922400/pubmed" id="922400" target="_blank">922400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27629844">
<a name="27629844"></a>Iwańczak BM, Borys-Iwanicka A, Biernat M, Gościniak G. Assessment of sequential and standard triple therapy in treatment of Helicobacter pylori infection in children dependent on bacteria sensitivity to antibiotics. <i>Adv Clin Exp Med</i>. 2016;25(4):701-708. doi:10.17219/acem/38554<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27629844/pubmed" id="27629844" target="_blank">27629844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18003962">
<a name="18003962"></a>Jacobs DO. Clinical practice. Diverticulitis. <i>N Engl J Med</i>. 2007;357(20):2057-2066.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18003962/pubmed" id="18003962" target="_blank">18003962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7062220">
<a name="7062220"></a>Jager-Roman E, Doyle PE, Baird-Lambert J, Cvejic M, Buchanan N. Pharmacokinetics and tissue distribution of metronidazole in the new born infant. <i>J Pediatr</i>. 1982;100(4):651-654.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7062220/pubmed" id="7062220" target="_blank">7062220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34164674">
<a name="34164674"></a>Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. <i>Clin Infect Dis</i>. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/34164674/pubmed" id="34164674" target="_blank">34164674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28541262">
<a name="28541262"></a>Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). <i>J Pediatr Gastroenterol Nutr</i>. 2017;64(6):991-1003. doi:10.1097/MPG.0000000000001594<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28541262/pubmed" id="28541262" target="_blank">28541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10761537">
<a name="10761537"></a>Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC. Evaluation of metronidazole toxicity: a prospective study. <i>Int J Clin Pharmacol Res</i>. 1999;19(3):83-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/10761537/pubmed" id="10761537" target="_blank">10761537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kelly.1">
<a name="Kelly.1"></a>Kelly CP, Lamont JT, Bakken JS. Clostridioides difficile infection in adults: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34003176">
<a name="34003176"></a>Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. <i>Am J Gastroenterol</i>. 2021;116(6):1124-1147. doi:10.14309/ajg.0000000000001278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/34003176/pubmed" id="34003176" target="_blank">34003176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18664895">
<a name="18664895"></a>Khan AY, Golewale MH, Kahn DA. A case of chronic drug-induced neutropenia. <i>J Psychiatr Pract</i>. 2008;14(4):246-250. doi:10.1097/01.pra.0000327316.27023.5d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18664895/pubmed" id="18664895" target="_blank">18664895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17339628">
<a name="17339628"></a>Khan S, Sharrack B, Sewell WA. Metronidazole-induced aseptic meningitis during <i>Helicobacter pylori</i> eradication therapy. <i>Ann Intern Med</i>. 2007;146(5):395-396. doi:10.7326/0003-4819-146-5-200703060-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/17339628/pubmed" id="17339628" target="_blank">17339628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21423852">
<a name="21423852"></a>Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. <i>J Acquir Immune Defic Syndr</i>. 2010;55(5):565-571. doi:10.1097/QAI.0b013e3181eda955<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21423852/pubmed" id="21423852" target="_blank">21423852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30297322">
<a name="30297322"></a>Kissinger P, Muzny CA, Mena LA, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial. <i>Lancet Infect Dis</i>. 2018;18(11):1251-1259. doi:10.1016/S1473-3099(18)30423-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/30297322/pubmed" id="30297322" target="_blank">30297322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Klompas.1">
<a name="Klompas.1"></a>Klompas M. Aspiration pneumonia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21558964">
<a name="21558964"></a>Koletzko S, Jones NL, Goodman KJ, et al. Evidence-Based Guidelines From ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> Infection in Children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):230-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21558964/pubmed" id="21558964" target="_blank">21558964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21996645">
<a name="21996645"></a>Kuriyama A, Jackson JL, Doi A, Kamiya T. Metronidazole-induced central nervous system toxicity: a systematic review. <i>Clin Neuropharmacol</i>. 2011;34(6):241-247. doi:10.1097/WNF.0b013e3182334b35<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21996645/pubmed" id="21996645" target="_blank">21996645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25171023">
<a name="25171023"></a>Kutluk G, Tutar E, Bayrak A, et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?. <i>Eur J Gastroenterol Hepatol</i>. 2014;26(11):1202-1208. doi:10.1097/MEG.0000000000000190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/25171023/pubmed" id="25171023" target="_blank">25171023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lamont.1">
<a name="Lamont.1"></a>Lamont JT. Treatment regimens for Helicobacter pylori. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10384859">
<a name="10384859"></a>Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. <i>Clin Pharmacokinet</i>. 1999;36(5):353-373. doi:10.2165/00003088-199936050-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/10384859/pubmed" id="10384859" target="_blank">10384859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3717930">
<a name="3717930"></a>Lau AH, Chang CW, Sabatini S. Hemodialysis clearance of metronidazole and its metabolites. <i>Antimicrob Agents Chemother</i>. 1986;29(2):235-238. doi:10.1128/aac.29.2.235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3717930/pubmed" id="3717930" target="_blank">3717930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3435113">
<a name="3435113"></a>Lau AH, Evans R, Chang CW, Seligsohn R. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. <i>Antimicrob Agents Chemother</i>. 1987;31(11):1662-1664. doi:10.1128/AAC.31.11.1662<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3435113/pubmed" id="3435113" target="_blank">3435113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leder.2018a">
<a name="Leder.2018a"></a>Leder K, Weller PF. Intestinal Entamoeba histolytica amebiasis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leder.2018b">
<a name="Leder.2018b"></a>Leder K, Weller PF. Extraintestinal Entamoeba histolytica amebiasis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 8, 2018b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29420227">
<a name="29420227"></a>Levine A, Kori M, Kierkus J, et al. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease: a randomised controlled trial. <i>Gut</i>. 2019;68(2):239-247. doi:10.1136/gutjnl-2017-315199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29420227/pubmed" id="29420227" target="_blank">29420227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29375866">
<a name="29375866"></a>Lew J, Berenberg J. Metronidazole caused profound drug-induced immune thrombocytopenia. <i>Clin Case Rep</i>. 2017;6(1):206-208. doi:10.1002/ccr3.1334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29375866/pubmed" id="29375866" target="_blank">29375866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8863036">
<a name="8863036"></a>Li E, Stanley SL Jr. Protozoa. Amebiasis. <i>Gastroenterol Clin North Am</i>. 1996;25(3):471-492.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/8863036/pubmed" id="8863036" target="_blank">8863036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19174807">
<a name="19174807"></a>Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's Disease in Adults. <i>Am J Gastroenterol</i>. 2009;104(2):465-483.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/19174807/pubmed" id="19174807" target="_blank">19174807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610508">
<a name="29610508"></a>Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults [published correction appears in <i>Am J Gastroenterol</i>. 2018;113(7):1101]. <i>Am J Gastroenterol</i>. 2018;113(4):481-517. doi:10.1038/ajg.2018.27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29610508/pubmed" id="29610508" target="_blank">29610508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Likmez.1">
<a name="Likmez.1"></a>Likmez (metronidazole) [prescribing information]. Hauppauge, NY: Saptalis Pharmaceuticals LLC; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31668170">
<a name="31668170"></a>Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the American Dental Association. <i>J Am Dent Assoc</i>. 2019;150(11):906-921.e12. doi:10.1016/j.adaj.2019.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31668170/pubmed" id="31668170" target="_blank">31668170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2037955">
<a name="2037955"></a>Loesche WJ, Schmidt E, Smith BA, et al. Effects of Metronidazole on Periodontal Treatment Needs. <i>J Periodontol</i>. 1991;62(4):247-257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/2037955/pubmed" id="2037955" target="_blank">2037955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1602034">
<a name="1602034"></a>Loesche WJ, Giordano JR, Hujoel P, et al. Metronidazole in Periodontitis: Reduced Need for Surgery. <i>J Clin Periodontol</i>. 1992;19(2):103-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/1602034/pubmed" id="1602034" target="_blank">1602034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28402454">
<a name="28402454"></a>Lopez-Sanromán A, Vera-Mendoza I, Domènech E, et al; Spanish GETECCU group [APPRECIA study]. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial.<i> J Crohns Colitis</i>. 2017;11(11):1293-1301. doi:10.1093/ecco-jcc/jjx051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28402454/pubmed" id="28402454" target="_blank">28402454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948039">
<a name="30948039"></a>Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. <i>Am J Obstet Gynecol.</i> 2019;220(4):308-323. doi:10.1016/j.ajog.2019.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/30948039/pubmed" id="30948039" target="_blank">30948039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12642754">
<a name="12642754"></a>Mahl TC, Ummadi S. Metronidazole and mental confusion. <i>J Clin Gastroenterol</i>. 2003;36(4):373-374. doi:10.1097/00004836-200304000-00024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/12642754/pubmed" id="12642754" target="_blank">12642754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258668">
<a name="21258668"></a>Malik BA, Xie YY, Wine E, Huynh HQ. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. <i>Can J Gastroenterol</i>. 2011;25(1):41-45. doi:10.1155/2011/604643<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21258668/pubmed" id="21258668" target="_blank">21258668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24550598">
<a name="24550598"></a>Mazumdar G, Shome K. Stevens-Johnson syndrome following use of metronidazole in a dental patient. <i>Indian J Pharmacol</i>. 2014;46(1):121-122. doi:10.4103/0253-7613.125193<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/24550598/pubmed" id="24550598" target="_blank">24550598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76. doi:10.1089/sur.2016.261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29462280">
<a name="29462280"></a>McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for <i>Clostridium difficile</i> infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). <i>Clin Infect Dis</i>. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29462280/pubmed" id="29462280" target="_blank">29462280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29027242">
<a name="29027242"></a>McGowan K, McGowan T, Ivanovski S. Optimal dose and duration of amoxicillin-plus-metronidazole as an adjunct to non-surgical periodontal therapy: a systematic review and meta-analysis of randomized, placebo-controlled trials. <i>J Clin Periodontol</i>. 2018;45(1):56-67. doi:10.1111/jcpe.12830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29027242/pubmed" id="29027242" target="_blank">29027242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17760644">
<a name="17760644"></a>McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. <i>Clin Exp Ophthalmol</i>. 2007;35(6):585-586. doi:10.1111/j.1442-9071.2007.01537.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/17760644/pubmed" id="17760644" target="_blank">17760644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871085">
<a name="31871085"></a>Mergenhagen KA, Wattengel BA, Skelly MK, Clark CM, Russo TA. Fact versus fiction: a review of the evidence behind alcohol and antibiotic interactions. <i>Antimicrob Agents Chemother</i>. 2020;64(3):e02167-19. doi:10.1128/AAC.02167-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31871085/pubmed" id="31871085" target="_blank">31871085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Braun.1">
<a name="Braun.1"></a>Metronidazole injection [prescribing information]. Bethlehem, PA: Braun Medical Inc; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Metronidazole injection USP [product monograph]. Mississauga, Quebec, Canada: Baxter Corporation; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Metronidazole injection USP [prescribing information]. Lake Forest, IL: Hospira Inc; October 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Metronidazole injection in sodium chloride [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Westward.1">
<a name="Westward.1"></a>Metronidazole injection in sodium chloride [prescribing information]. Eatontown, NJ: West-ward Injectables; received November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.2">
<a name="Baxter.2"></a>Metronidazole injection in sodium chloride in plastic container [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Metronidazole tablet [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631728">
<a name="28631728"></a>Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi:10.1038/ajg.2017.154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28631728/pubmed" id="28631728" target="_blank">28631728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27547155">
<a name="27547155"></a>Mojadidi MK, Hovnanians N, Kaufmann MR, Hill JA. An unusual presentation of QT prolongation. <i>Tex Heart Inst J</i>. 2016;43(4):367-368. Published Aug 1, 2016. doi:10.14503/THIJ-16-5931<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27547155/pubmed" id="27547155" target="_blank">27547155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34183510">
<a name="34183510"></a>Mora-López L, Ruiz-Edo N, Estrada-Ferrer O, et al; DINAMO-study group. Efficacy and safety of nonantibiotic outpatient treatment in mild acute diverticulitis (DINAMO-study): a multicentre, randomised, open-label, noninferiority trial. <i>Ann Surg</i>. 2021;274(5):e435-e442. doi:10.1097/SLA.0000000000005031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/34183510/pubmed" id="34183510" target="_blank">34183510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172284">
<a name="21172284"></a>Mottet C, Vader JP, Felley C, et al. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. <i>J Crohns Colitis</i>. 2009; 3(4):257-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21172284/pubmed" id="21172284" target="_blank">21172284</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8703652">
<a name="8703652"></a>Muscara MN, Pedrazzoli J Jr, Miranda EL, et al. Plasma hydroxy-metronidazole/metronidazole ratio in patients with liver disease and in healthy volunteers. <i>Br J Clin Pharmacol.</i> 1995;40(5):477-480. doi:10.1111/j.1365-2125.1995.tb05792.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/8703652/pubmed" id="8703652" target="_blank">8703652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24533282">
<a name="24533282"></a>Nagata N, Marriott D, Harkness J, Ellis JT, Stark D. Current treatment options for Dientamoeba fragilis infections. <i>Int J Parasitol Drugs Drug Resist</i>. 2012;2:204-215. doi:10.1016/j.ijpddr.2012.08.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/24533282/pubmed" id="24533282" target="_blank">24533282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35274342">
<a name="35274342"></a>Namjoshi SS, Galloway D, Herdes RE, Talathi S, Ding VY, Mezoff EA. Bacterial overgrowth assessment and treatment among pediatric intestinal rehabilitation and nutrition support providers: an international survey of clinical practice patterns. <i>JPEN J Parenter Enteral Nutr</i>. 2022;46(8):1914-1922. doi:10.1002/jpen.2369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/35274342/pubmed" id="35274342" target="_blank">35274342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19817675">
<a name="19817675"></a>Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. <i>Expert Rev Gastroenterol Hepatol</i>. 2009;3(5):547-559. doi:10.1586/egh.09.37<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/19817675/pubmed" id="19817675" target="_blank">19817675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27840074">
<a name="27840074"></a>Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of Crohn's disease after surgical resection. <i>Gastroenterology</i>. 2017;152(1):271-275. doi:10.1053/j.gastro.2016.10.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27840074/pubmed" id="27840074" target="_blank">27840074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31785173">
<a name="31785173"></a>Nguyen N, Zhang B, Holubar SD, Pardi DS, Singh S. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. <i>Cochrane Database Syst Rev</i>. 2019;11(11):CD001176. doi:10.1002/14651858.CD001176.pub5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31785173/pubmed" id="31785173" target="_blank">31785173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7486930">
<a name="7486930"></a>Nix DE, Tyrrell R, Müller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. <i>Antimicrob Agents Chemother.</i> 1995;39(8):1848-1852. doi:10.1128/AAC.39.8.1848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7486930/pubmed" id="7486930" target="_blank">7486930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17595541">
<a name="17595541"></a>Odenholt I, Walder M, Wullt M. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile. <i>Chemotherapy</i>. 2007;53(4):267-274. doi:10.1159/000104471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/17595541/pubmed" id="17595541" target="_blank">17595541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20862338">
<a name="20862338"></a>O'Halloran E, Hogan A, Mealy K. Metronidazole-induced pancreatitis. <i>HPB Surg</i>. 2010;2010:523468. doi:10.1155/2010/523468<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20862338/pubmed" id="20862338" target="_blank">20862338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29186570">
<a name="29186570"></a>Ordóñez-Mena JM, McCarthy ND, Fanshawe TR. Comparative efficacy of drugs for treating giardiasis: a systematic update of the literature and network meta-analysis of randomized clinical trials. <i>J Antimicrob Chemother</i>. 2018;73(3):596-606. doi:10.1093/jac/dkx430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/29186570/pubmed" id="29186570" target="_blank">29186570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6307965">
<a name="6307965"></a>Pais P, Balasubramaniam KR. Metronidazole-peripheral neuropathy. <i>J Assoc Physicians India</i>. 1982;30(12):918-919.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6307965/pubmed" id="6307965" target="_blank">6307965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3203060">
<a name="3203060"></a>Passmore CM, McElnay JC, Rainey EA, et al. Metronidazole excretion in human milk and its effect on the suckling neonate. <i>Br J Clin Pharmacol</i>. 1988;26(1):45-51. doi:10.1111/j.1365-2125.1988.tb03362.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3203060/pubmed" id="3203060" target="_blank">3203060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18511323">
<a name="18511323"></a>Patel K, Green-Hopkins I, Lu S, Tunkel AR. Cerebellar ataxia following prolonged use of metronidazole: case report and literature review. <i>Int J Infect Dis</i>. 2008;12(6):e111-114. doi:10.1016/j.ijid.2008.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18511323/pubmed" id="18511323" target="_blank">18511323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37168915">
<a name="37168915"></a>Peinado Fabregat MI, Gardner RM, Hassan MA, Kapphahn K, Yeh AM. Small intestinal bacterial overgrowth in children: clinical features and treatment response. <i>JPGN Rep</i>. 2022;3(2):e185. doi:10.1097/PG9.0000000000000185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/37168915/pubmed" id="37168915" target="_blank">37168915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pemberton.2018">
<a name="Pemberton.2018"></a>Pemberton JH. Acute colonic diverticulitis: medical management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19568226">
<a name="19568226"></a>Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. <i>Am J Gastroenterol</i>. 2009;104(8):2089-2096. doi:10.1038/ajg.2009.301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/19568226/pubmed" id="19568226" target="_blank">19568226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34156541">
<a name="34156541"></a>Phyo LY, Singkhamanan K, Laochareonsuk W, et al. Fecal microbiome alterations in pediatric patients with short bowel syndrome receiving a rotating cycle of gastrointestinal prophylactic antibiotics. <i>Pediatr Surg Int</i>. 2021;37(10):1371-1381. doi:10.1007/s00383-021-04948-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/34156541/pubmed" id="34156541" target="_blank">34156541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31692663">
<a name="31692663"></a>Phyu H, Edmond MB, Kobayashi T. Metronidazole-induced encephalopathy. <i>IDCases</i>. 2019;18:e00639. doi:10.1016/j.idcr.2019.e00639<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31692663/pubmed" id="31692663" target="_blank">31692663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32023228">
<a name="32023228"></a>Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. <i>Am J Gastroenterol</i>. 2020;115(2):165-178. doi:10.14309/ajg.0000000000000501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/32023228/pubmed" id="32023228" target="_blank">32023228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33409111">
<a name="33409111"></a>Puri P, Parnami P, Chitkara A, Athwal PSS, Khetrapal S. Antibiomania: A rare case of metronidazole-induced mania. <i>Cureus</i>. 2021;13(1):e12414. doi:10.7759/cureus.12414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/33409111/pubmed" id="33409111" target="_blank">33409111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1957918">
<a name="1957918"></a>Putnam D, Fraunfelder FT, Dreis M. Metronidazole and optic neuritis. <i>Am J Ophthalmol</i>. 1991;112(6):737. doi:10.1016/s0002-9394(14)77290-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/1957918/pubmed" id="1957918" target="_blank">1957918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26087839">
<a name="26087839"></a>Rabelo CC, Feres M, Gonçalves C, et al. Systemic antibiotics in the treatment of aggressive periodontitis. A systematic review and a Bayesian Network meta-analysis. <i>J Clin Periodontol</i>. 2015;42(7):647-657. doi:10.1111/jcpe.12427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/26087839/pubmed" id="26087839" target="_blank">26087839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19704395">
<a name="19704395"></a>Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. <i>Sex Transm Dis</i>. 2009;36(11):732-734. doi:10.1097/OLQ.0b013e3181b08456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/19704395/pubmed" id="19704395" target="_blank">19704395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23656647">
<a name="23656647"></a>Ross AG, Olds GR, Cripps AW, Farrar JJ, McManus DP. Enteropathogens and chronic illness in returning travelers. <i>N Engl J Med</i>. 2013;368(19):1817-1825. doi:10.1056/NEJMra1207777<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23656647/pubmed" id="23656647" target="_blank">23656647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27504340">
<a name="27504340"></a>Roy U, Panwar A, Pandit A, Das SK, Joshi B. Clinical and neuroradiological spectrum of metronidazole induced encephalopathy: our experience and the review of literature. <i>J Clin Diagn Res</i>. 2016;10(6):OE01-OE09. doi:10.7860/JCDR/2016/19032.8054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27504340/pubmed" id="27504340" target="_blank">27504340</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3956567">
<a name="3956567"></a>Rubenson A, Rosetzsky A. Single dose prophylaxis with metronidazole in infants during abdominal surgery: a pharmacokinetic study. <i>Eur J Clin Pharmacol.</i> 1986;29(5):625-628. doi:10.1007/BF00635904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3956567/pubmed" id="3956567" target="_blank">3956567</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22516861">
<a name="22516861"></a>Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22516861/pubmed" id="22516861" target="_blank">22516861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7768364">
<a name="7768364"></a>Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. <i>Gastroenterology</i>. 1995;108(6):1617-1621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/7768364/pubmed" id="7768364" target="_blank">7768364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31736605">
<a name="31736605"></a>Sagvekar Y, Shah V, Rohatgi A, et al. Short-course self-medication of metronidazole leading to acute toxic encephalopathy and ataxia. <i>Ann Indian Acad Neurol</i>. 2019;22(4):543-545. doi:10.4103/aian.AIAN_43_19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31736605/pubmed" id="31736605" target="_blank">31736605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11856075">
<a name="11856075"></a>Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis--a double-blind, double-dummy, controlled trial. <i>Aliment Pharmacol Ther.</i> 2002;16(1):27-34. doi:10.1046/j.1365-2036.2002.01139.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/11856075/pubmed" id="11856075" target="_blank">11856075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20081543">
<a name="20081543"></a>Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. <i>J Pediatr Gastroenterol Nutr</i>. 2010;50(Suppl 1):S1-S13. doi:10.1097/MPG.0b013e3181c92c53<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20081543/pubmed" id="20081543" target="_blank">20081543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24257215">
<a name="24257215"></a>Sarna JR, Furtado S, Brownell AK. Neurologic complications of metronidazole. <i>Can J Neurol Sci</i>. 2013;40(6):768-776. doi:10.1017/s0317167100015870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/24257215/pubmed" id="24257215" target="_blank">24257215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992746">
<a name="25992746"></a>Sawyer RG, Claridge JA, Nathens AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21):1996-2005. doi:10.1056/NEJMoa1411162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/25992746/pubmed" id="25992746" target="_blank">25992746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18854484">
<a name="18854484"></a>Schuster FL, Ramirez-Avila L. Current world status of Balantidium coli. <i>Clin Micro Rev</i>. 2008;21(4):626-638.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18854484/pubmed" id="18854484" target="_blank">18854484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23277317">
<a name="23277317"></a>Schutze GE, Willoughby RE; Committee on Infectious Diseases, American Academy of Pediatrics. Clostridium difficile infection in infants and children. <i>Pediatrics</i>. 2013;131(1):196-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23277317/pubmed" id="23277317" target="_blank">23277317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407111">
<a name="21407111"></a>Schwarzer A, Urruzuno P, Iwańczak B, et al. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. <i>J Pediatr Gastroenterol Nutr</i>. 2011;52(4):424-428. doi:10.1097/MPG.0b013e3181fc8c58<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21407111/pubmed" id="21407111" target="_blank">21407111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2018b">
<a name="Sexton.2018b"></a>Sexton DJ, Sampson JH. Intracranial epidural abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 18, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33524402">
<a name="33524402"></a>Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. <i>Gastroenterology</i>. 2021;160(5):1831-1841. doi:10.1053/j.gastro.2020.11.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/33524402/pubmed" id="33524402" target="_blank">33524402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28719679">
<a name="28719679"></a>Shah SD, Cifu AS. Management of acute diverticulitis. <i>JAMA</i>. 2017;318(3):291-292. doi:10.1001/jama.2017.6373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28719679/pubmed" id="28719679" target="_blank">28719679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shen.2020">
<a name="Shen.2020"></a>Shen B. Management of acute and chronic pouchitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shih.2018">
<a name="Shih.2018"></a>Shih G, Wallace R. First-trimester pregnancy termination: uterine aspiration. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23297772">
<a name="23297772"></a>Silva-Senem MX, Heller D, Varela VM, Torres MC, Feres-Filho EJ, Colombo AP. Clinical and microbiological effects of systemic antimicrobials combined to an anti-infective mechanical debridement for the management of aggressive periodontitis: a 12-month randomized controlled trial. <i>J Clin Periodontol</i>. 2013;40(3):242-251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23297772/pubmed" id="23297772" target="_blank">23297772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33902072">
<a name="33902072"></a>Smith MJ, Boutzoukas A, Autmizguine J, et al. Antibiotic safety and effectiveness in premature infants with complicated intraabdominal infections. <i>Pediatr Infect Dis J</i>. 2021;40(6):550-555. doi:10.1097/INF.0000000000003034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/33902072/pubmed" id="33902072" target="_blank">33902072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.1">
<a name="Sobel.1"></a>Sobel JD. Bacterial vaginosis: Initial treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sobel.2">
<a name="Sobel.2"></a>Sobel JD, Mitchell C. Trichomoniasis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33642295">
<a name="33642295"></a>Soh Y. Metronidazole-induced recurrent paresthesia: a case report. <i>Neurol India</i>. 2021;69(1):174-176. doi: 10.4103/0028-3886.310097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/33642295/pubmed" id="33642295" target="_blank">33642295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America [published correction appears in <i>Clin Infect Dis</i>. 2010;50(12):1695]. <i>Clin Infect Dis.</i> 2010;50(2):133-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6706889">
<a name="6706889"></a>Somogyi AA, Kong CB, Gurr FW, Sabto J, Spicer WJ, McLean AJ. Metronidazole pharmacokinetics in patients with acute renal failure. <i>J Antimicrob Chemother</i>. 1984;13(2):183-189. doi:10.1093/jac/13.2.183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6706889/pubmed" id="6706889" target="_blank">6706889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30536109">
<a name="30536109"></a>Sørensen CG, Karlsson WK, Amin FM, Lindelof M. Metronidazole-induced encephalopathy: a systematic review. <i>J Neurol</i>. 2020;267(1):1-13. doi:10.1007/s00415-018-9147-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/30536109/pubmed" id="30536109" target="_blank">30536109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Southwick.2018">
<a name="Southwick.2018"></a>Southwick FS. Treatment and prognosis of bacterial brain abscess. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16887471">
<a name="16887471"></a>Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. <i>Diagn Microbiol Infect Dis</i>. 2006;55(4):303-309. doi:10.1016/j.diagmicrobio.2006.06.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/16887471/pubmed" id="16887471" target="_blank">16887471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15561831">
<a name="15561831"></a>Sprandel KA, Schriever CA, Pendland SL, et al. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects. <i>Antimicrob Agents Chemother.</i> 2004;48(12):4597-605. doi:10.1128/AAC.48.12.4597-4605.2004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/15561831/pubmed" id="15561831" target="_blank">15561831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America [published online ahead of print June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677904">
<a name="16677904"></a>St. Peter SD, Little DC, Calkins CM, et al. A simple and more cost-effective antibiotic regimen for perforated appendicitis. <i>J Pediatr Surg</i>. 2006;41(5):1020-1024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/16677904/pubmed" id="16677904" target="_blank">16677904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18558169">
<a name="18558169"></a>St. Peter SD, Tsao K, Spilde TL, et al. Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial. <i>J Pediatr Surg</i>. 2008;43(6):981-985.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/18558169/pubmed" id="18558169" target="_blank">18558169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12105831">
<a name="12105831"></a>Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. <i>Gastroenterology</i>. 2002;123(1):33-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/12105831/pubmed" id="12105831" target="_blank">12105831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31799497">
<a name="31799497"></a>Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn's disease: the Toronto Consensus. <i>J Can Assoc Gastroenterol</i>. 2018;1(4):141-154. doi:10.1093/jcag/gwy047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31799497/pubmed" id="31799497" target="_blank">31799497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26453777">
<a name="26453777"></a>Stollman N, Smalley W, Hirano I; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of acute diverticulitis. <i>Gastroenterology</i>. 2015;149(7):1944-1949. doi:10.1053/j.gastro.2015.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/26453777/pubmed" id="26453777" target="_blank">26453777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23974062">
<a name="23974062"></a>Tahan S, Melli LC, Mello CS, Rodrigues MS, Bezerra Filho H, de Morais MB. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. <i>J Pediatr Gastroenterol Nutr</i>. 2013;57(3):316-318. doi:10.1097/MPG.0b013e3182952e93<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23974062/pubmed" id="23974062" target="_blank">23974062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16181387">
<a name="16181387"></a>Talley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia. <i>Am J Gastroenterol.</i> 2005;100(10):2324-2337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/16181387/pubmed" id="16181387" target="_blank">16181387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5898094">
<a name="5898094"></a>Taylor JA. Metronidazole and transient leukopenia. <i>JAMA</i>. 1965;194(12):1331-1332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/5898094/pubmed" id="5898094" target="_blank">5898094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thwaites.1">
<a name="Thwaites.1"></a>Thwaites L. Tetanus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16163635">
<a name="16163635"></a>Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. <i>Clin Infect Dis.</i> 2005;41(8):1159-1166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/16163635/pubmed" id="16163635" target="_blank">16163635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30044357">
<a name="30044357"></a>Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;67(2):257-291. doi:10.1097/MPG.0000000000002035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/30044357/pubmed" id="30044357" target="_blank">30044357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3357144">
<a name="3357144"></a>Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. <i>J Pediatr Surg</i>. 1988;23(3):263-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/3357144/pubmed" id="3357144" target="_blank">3357144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Accessed May 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27663456">
<a name="27663456"></a>VanCleave HZ, Sanchez AC, Lieberman JA, Ellenburg JT, Mabry WA. Probable metronidazole induced serum sickness-like reaction in a paediatric patient. <i>J Clin Pharm Ther</i>. 2016;41(6):736-738. doi:10.1111/jcpt.12448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27663456/pubmed" id="27663456" target="_blank">27663456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073652">
<a name="32073652"></a>van Dijk ST, Chabok A, Dijkgraaf MG, Boermeester MA, Smedh K. Observational versus antibiotic treatment for uncomplicated diverticulitis: an individual-patient data meta-analysis. <i>Br J Surg</i>. 2020;107(8):1062-1069. doi:10.1002/bjs.11465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/32073652/pubmed" id="32073652" target="_blank">32073652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33026087">
<a name="33026087"></a>van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. <i>J Crohns Colitis</i>. Published online October 7, 2020. doi:10.1093/ecco-jcc/jjaa161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/33026087/pubmed" id="33026087" target="_blank">33026087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30015369">
<a name="30015369"></a>van Wattum JJ, Leferink TM, Wilffert B, Ter Horst PGJ. Antibiotics and lactation: an overview of relative infant doses and a systematic assessment of clinical studies. <i>Basic Clin Pharmacol Toxicol.</i> 2019;124(1):5-17. doi:10.1111/bcpt.13098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/30015369/pubmed" id="30015369" target="_blank">30015369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21235333">
<a name="21235333"></a>Varela VM, Heller D, Silva-Senem MX, et al. Systemic Antimicrobials Adjunctive to a Repeated Mechanical and Antiseptic Therapy for Aggressive Periodontitis: A 6-Month Randomized Controlled Trial. <i>J Periodontol.</i> 2011;82(8):1121-1130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21235333/pubmed" id="21235333" target="_blank">21235333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12022894">
<a name="12022894"></a>Visapää JP, Tillonen JS, Kaihovaara PS, Salaspuro MP. Lack of disulfiram-like reaction with metronidazole and ethanol. <i>Ann Pharmacother</i>. 2002;36(6):971-974. doi:10.1345/aph.1A066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/12022894/pubmed" id="12022894" target="_blank">12022894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6725177">
<a name="6725177"></a>Visser AA, Hundt HK. The Pharmacokinetics of a Single Intravenous Dose of Metronidazole in Pregnant Patients. <i>J Antimicrob Chemother.</i> 1984;13(3):279-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/6725177/pubmed" id="6725177" target="_blank">6725177</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vollmer.2019">
<a name="Vollmer.2019"></a>Vollmer CM, Zakko SF, Afdhal NH. Treatment of acute calculous cholecystitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 10, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21775695">
<a name="21775695"></a>Wall GC, Shirmer LL, Anliker LE, Tigges AE. Pharmacotherapy for acute pouchitis. <i>Ann Pharmacother</i>. 2011;45(9):1127-1137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/21775695/pubmed" id="21775695" target="_blank">21775695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20608802">
<a name="20608802"></a>Wang X, Nanovskaya TN, Zhan Y, et al. Pharmacokinetics of Metronidazole in Pregnant Patients With Bacterial Vaginosis. <i>J Matern Fetal Neonatal Med.</i> 2011;24(3):444-448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/20608802/pubmed" id="20608802" target="_blank">20608802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25381839">
<a name="25381839"></a>Wang B, Wang YH, Lv ZF, et al. Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. <i>Helicobacter</i>. 2015;20(2):79-88. doi:10.1111/hel.12180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/25381839/pubmed" id="25381839" target="_blank">25381839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weller.2018">
<a name="Weller.2018"></a>Weller PF, Leder K. Balantidium coli infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32052831">
<a name="32052831"></a>Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL. A randomized controlled trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of acute pelvic inflammatory disease. <i>Clin Infect Dis</i>. Published online February 13, 2020. doi:10.1093/cid/ciaa101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/32052831/pubmed" id="32052831" target="_blank">32052831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilder.2019">
<a name="Wilder.2019"></a>Wilder RS, Moretti AJ. Overview of gingivitis and periodontitis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10676835">
<a name="10676835"></a>Williams CS, Woodcock KR. Do ethanol and metronidazole interact to produce a disulfiram-like reaction? <i>Ann Pharmacother</i>. 2000;34(2):255-257. doi:10.1345/aph.19118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/10676835/pubmed" id="10676835" target="_blank">10676835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-357408">
<a name="357408"></a>Willis AT, Ferguson IR, Jones PH, et al. An evaluation of metronidazole in the prophylaxis of anaerobic infections in obstetrical patients. <i>J Antimicrob Chemother.</i> 1978;4(suppl C):55-62. doi:10.1093/jac/4.suppl_c.55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/357408/pubmed" id="357408" target="_blank">357408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23215911">
<a name="23215911"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. http://apps.who.int/iris/bitstream/handle/10665/62435/55732.pdf;jsessionid=6B47B933AC2796FD49DA7C70B703CFA9?sequence=1
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/23215911/pubmed" id="23215911" target="_blank">23215911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guidelines for the management of symptomatic sexually transmitted infections. Published July 15, 2021. Accessed October 24, 2022. https://www.who.int/publications/i/item/9789240024168.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22870180">
<a name="22870180"></a>Yamamoto T, Abe K, Anjiki H, Ishii T, Kuyama Y. Metronidazole-induced neurotoxicity developed in liver cirrhosis. <i>J Clin Med Res.</i> 2012;4(4):295-298. doi:10.4021/jocmr893w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/22870180/pubmed" id="22870180" target="_blank">22870180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yardeni.1">
<a name="Yardeni.1"></a>Yardeni D, Kawar B, Siplovich L, et al. Single daily dosing of ceftriaxone and metronidazole is as safe and effective as ampicillin, gentamicin and metronidazole for non-operative management of complicated appendicitis in children. <i>Pediat Therapeut</i>. 2013;3:5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27821041">
<a name="27821041"></a>Yilmaz M, Kinikoglu O, Ceyla B, Arslan F, Mert A. Recurrent pancreatitis induced by metronidazole re-exposure and a review of the current literature. <i>Acta Gastroenterol Belg</i>. 2016;79(3):389-390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/27821041/pubmed" id="27821041" target="_blank">27821041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31281684">
<a name="31281684"></a>Youssef I, Saeed N, El Abdallah M, Huevelhorst K, Zakharia K. Metronidazole-induced pancreatitis: Is there underrecognition? A case report and systematic review of the literature. <i>Case Rep Gastrointest Med</i>. 2019;2019:4840539. doi:10.1155/2019/4840539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/31281684/pubmed" id="31281684" target="_blank">31281684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28729110">
<a name="28729110"></a>Yudin MH, Money DM. No. 211-Screening and management of bacterial vaginosis in pregnancy. <i>J Obstet Gynaecol Can</i>. 2017;39(8):e184-e191. doi:10.1016/j.jogc.2017.04.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/metronidazole-systemic-pediatric-drug-information/abstract-text/28729110/pubmed" id="28729110" target="_blank">28729110</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16019 Version 634.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
